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This dissertation focuses on the development of two novel ultrasound technologies with 
the idea of tracking and locating small particles: 1) Ultrasound tracking of the acoustically actuated 
microswimmers, 2) Super-resolution ultrasound (SRU) imaging by locating the microbubbles. 
Artificial microswimmers that navigate in hard-to-reach spaces and microfluidic 
environments inside human bodies hold a great potential for various biomedical applications. For 
eventual translation of the microswimmer technology, a capability of tracking the microswimmers 
in 3-D through tissues is particularly required for reliable navigation. In this work, after first 
proposing and demonstrating the proof-of-concept of ultrasound tracking of the microswimmer in 
a 2-D setup in vitro, we built a 3-D ultrasound tracking system using two clinical ultrasound 
probes.  A reliable performance for tracking the arbitrary 3-D motions of the newly designed 3-D 
microswimmers in real-time was demonstrated in vitro. The developed 3-D ultrasound tracking 
strategy could be a strong motivation and foundation for the future clinical translation of the novel 
microswimmer technology.  
SRU that can identify microvessels with unprecedented spatial resolution is promising for 
diagnosing the diseases associated with abnormal microvascular changes. One of the potential 
applications is to assess the changes in renal microvasculature during the progressive kidney 
disease. In this work, we applied the developed deconvolution-based SRU imaging on the mouse 
acute kidney injury (AKI) model to show the capability of SRU for noninvasive assessment of 
renal microvasculature changes during the progression from AKI to chronic kidney disease (CKD). 
 v 
The technology was then adapted to a clinical curved linear array probe and evaluated on both 
healthy human subjects and CKD patients. We also applied the SRU technology for identifying 
the vasa vasorum near rabbit femoral arteries that is a key biomarker for atherosclerosis plaque 
development. Overall, the study demonstrates a great potential of SRU as a diagnostic tool for 
these diseases and would promote the eventual clinical translations.  
Future endeavors for integrating SRU locating technology with a reliable tracking 
capability of microparticles will provide a unique tool for various biomedical applications of the 
novel microdrones for diagnosis and drug delivery. 
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This work focuses on the two topics with the idea of tracking and locating small particles: 
1) Ultrasound tracking of the acoustically actuated microswimmers, 2) Super-resolution 
ultrasound (SRU) imaging by locating the microbubbles. Novel ultrasound signal and image 
processing algorithms have been developed and applied to locate and track small particles for 
biomedical applications. 
In this section, the motivations and the specific objectives of the studies will be 
summarized. The overview of the organization of this dissertation will also be presented. 
1.1 Background and Motivations 
1.1.1 Ultrasound Tracking of the Acoustically Actuated Microswimmers 
Artificial microswimmers that navigate in hard-to-reach spaces and microfluidic 
environments inside human bodies have drawn increasing research interest over the past decades 
[1]–[4]. The microswimmers hold a great potential in various biomedical applications, including 
targeted drug delivery [5]–[8], microsurgery [8]–[11], particle separation and assembly [12]–[14], 
bio-sensing [8],  and further promote a revolution in medicine in the future [4], [15], [16]. Whereas 
there has been continued progress in designing and fabricating novel microswimmers for different 
applications, the major challenges still remain especially when considering practical propulsion, 
tracking, and control of the microswimmers in real biomedical environments [4], [17].  
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Concerning the propulsion of the microswimmers, a variety of approaches have been 
investigated, such as harness of biological [18], [19], chemical fuels [20]–[24], magnetic actuation 
[25]–[29]. However, they all have some limitations in practical applications. Harness of biological 
requires controlled environment for the bacteria to survive, which is challenging for in vivo 
applications. Chemical fuels are commonly not biocompatible and may do harm to the human 
body. Magnetic actuation attracted more interest among these mechanisms. However, the actuation 
in general requires a set of several bulky external coils to generate a strong magnetic field and the 
magnetic field is not compatible with some implanted devices. Acoustic actuation is promising 
and appealing in real biomedical environments, since it is noninvasive and biocompatible [30]–
[32]. Acoustic waves can travel through biological tissues to perform wireless actuations on 
microswimmers. Moreover, it would be a convenient and economic approach if translating into 
clinical practice. The microswimmers with air-filled cavity that are propelled by acoustic actuation 
have already been proposed[33]. The device contains a periodically oscillating gaseous bubble that 
is externally excited by acoustic waves. The propulsion mechanism is based on the fact that if the 
oscillating Reynolds number is not too small (typically around 100 for a good performance), the 
intake and discharge flow in the cavity is asymmetric, which propels the main body of the 
microswimmer. In earlier studies, the proof-of-concept has been successfully demonstrated using 
micro-fabricated microswimmers for selective and bi-directional propulsion [17], [33]–[36].  
Although acoustic actuation is promising, there is still a long way towards eventual 
translation of the microswimmer technology into practical in situ biomedical applications. One of 
the challenges is to track the microswimmers while they are actuated and navigate inside human 
bodies. A robust tracking strategy available for in situ applications is particularly required in order 
to locate the microswimmers in real-time and provide feedback for accurate control and 
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navigation. There has been a limited number of studies that focus on developing appropriate 
tracking strategies for biomedical applications of the microswimmers. Most of the studies use a 
camera to record the motion of microswimmers [17], [35], [36]. However, optical imaging is not 
accessible when the microswimmers are injected into the human body due to its short imaging 
depth in tissues. Thus, in order to translate the strategy of acoustic actuated microswimmer into 
clinical applications, a robust tracking strategy for microswimmers available for in vivo 
applications needs to be established. 
1.1.2 SRU Imaging 
The idea of locating and tracking ultrasound contrast agents like microbubbles also 
contributes to the development of the SRU imaging. SRU imaging [37]–[46], is an emerging 
technology that achieves a high spatial resolution of microvasculature imaging that breaks the 
acoustic diffraction limit [37]. The technology was inspired by the optical super-resolution 
imaging that was awarded the Noble Prize in Chemistry in 2014. The basic idea of optical super-
resolution technique, including fluorescence photoactivated localization microscopy [47], 
photoactivated localization microscopy (PALM) [48], and stochastic optical reconstruction 
microscopy (STORM) [49],  is to localize the centroid of each randomly blinking fluorescence 
sources based on the system point spread function (PSF). The location information of each blinking 
fluorophore is stacked up over a substantial sequential dataset that was captured by fast camera to 
form an image spatially resolved with sub-wavelength resolution. By this approach, the spatial 
resolution down to tens of nanometers was achieved. In SRU imaging, ultrasound contrast agents 
that travel through vascular network were utilized to replace the role of fluorophore in optical 
super-resolution, to implement the noninvasive imaging of microvasculature [38]. While the 
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spatial resolution that can be achieved by ultrasonic super-resolution was not comparable to that 
by optical super-resolution due to the much longer wavelength of the operating ultrasound 
compared to the light wavelength, the ultrasound approach achieved a much larger imaging depth. 
The technology components of SRU imaging mainly consists of ultrafast ultrasound imaging [50], 
clutter filter [51] that extracts microbubble signals, and the novel microbubble localization 
algorithms [38], [42], [43], [48], [49] that pinpoint the locations of the microbubbles. With these 
state-of-art technical components, the vascular structure and the blood flow can be reconstructed 
with unmatched spatial resolution up to one third of the wavelength of the ultrasound waves [37], 
significantly outperforming conventional contrast-enhanced ultrasound (CEU) approaches. 
In previous studies, the proof-of-concept of SRU imaging technology has been successfully 
tested in vivo to reconstruct the microvascular network and blood flow inside the organs of some 
small animals at very high resolution [38], [41], [42], [52], [53]. As an important next step towards 
translating this technology to clinical applications in future, a preclinical validation study in a 
specific disease model is particularly required. In this dissertation, the developed SRU technology 
was applied to two animal disease models. The mouse acute kidney injury (AKI) model was used 
for investigating the capability of SRU for assessing the abnormal microvascular changes during 
the injury progression. The technology was subsequently implemented into a clinical mid-
frequency probe for the human subject study with chronic kidney disease (CKD). For another 
important disease associated with atherosclerosis, the rabbit atherosclerotic plaque (AP) model 
was used for evaluating SRU technology capability in assessing vasa vasorum changes during the 
atherosclerotic plaque progress.  
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1.2 Objectives 
This work mainly consists of two projects, which include the ultrasound tracking of the 
microswimmers, and the SRU imaging of the microvasculature by locating the flowing 
microbubbles.  
The main objective of the microswimmer study is to:  
1) Demonstrate the proof-of-concept of ultrasound tracking using two clinical ultrasound 
array probes in 2-D setup using 2-D maneuverable microswimmers.  
2) Develop the 3-D ultrasound tracking strategy using two clinical ultrasound array probes 
fixed to a motor-controlled translational stage and evaluated the performance for 
tracking the arbitrary 3-D motion of a 3-D microswimmer in benchtop experiments. 
The main objective of the SRU project is to:  
1) develop the SRU imaging algorithm that can identify the microvasculature in vivo 
within a short scan time and evaluate the most achievable spatial resolution beyond the 
acoustic diffraction limit given operating ultrasound frequency through the benchtop 
experiments using uniquely designed microfluidic channels. 
2) demonstrate the in vivo capability of SRU technology for noninvasive assessment of 
the microvascular changes by imaging the renal microvasculature in the mouse AKI 
model, and by imaging the VV in the rabbit AP model. 
3) Adapt the SRU technology to a clinical curved array ultrasound probe for human 
kidney imaging and evaluate the performance on healthy human subject and CKD 
patients for demonstrating the translatability of the technology. 
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1.3 Organization of Dissertation 
Chapter 2 introduces the propulsion mechanism and the designs of the acoustically actuated 
microswimmer and demonstrates the proof-of-concept and accuracy of the ultrasound tracking 
using the 2D microswimmer that travels two-dimensionally in benchtop experiments. In the 
experiment, the ultrasound tracking results were compared with the synchronously operated 
camera tracking. A few typical moving trajectories including straight, instantaneous change in 
direction, and continuous change in direction like a circular motion, were realized by two different 
microswimmer designs to evaluate the tracking performance. A laboratory developed tracking 
algorithm was used to estimate the moving trajectories of the microswimmer captured by both 
camera and ultrasound.  
After demonstrating the proof-of-concept of ultrasound tracking of the microswimmers, 
we worked on the design and development of the 3-D ultrasound tracking system that hold 
potential for practical usefulness in situ in biomedical applications. In Chapter 3, the 3-D tracking 
system, including equipment and the imaging and tracking sequences, is presented. The 
performance of the 3-D tracking of the microswimmers that is designed to travel three-
dimensionally under acoustic actuation was evaluated by comparing with the camera tracking. 
Chapter 4 introduces the SRU imaging technology. The developed algorithm was tested 
through benchtop experiments using microfluidic channels, which mimic microvessels. The most 
achievable spatial resolution was evaluated in the experiment.  
In Chapter 5, the in vivo SRU imaging on the mouse AKI model is presented in which the 
capability of noninvasive quantification of renal vasculature changes associated with AKI-to-CKD 
progression in mice is shown. In the study, ultrasound scan was performed in vivo on mouse 
kidneys at 21 and 42 days after AKI, uninjured contralateral kidneys, as well as sham kidneys. The 
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changes in size, relative blood volume (rBV), vessel density, and vessel tortuosity, based on the 
reconstructed SRU kidney images were quantitatively assessed. The correlation between 
ultrasound  and histological assessment on the vessel density was calculated. 
After validating the feasibility of SRU technology for assessing the renal microvessels in 
the mouse model, we further worked on the adaptation of the algorithm into a clinical ultrasound 
curved array probe for the application on human kidney imaging. The performance of SRU 
imaging on the kidneys from both healthy human subjects and patients with CKD is shown in 
Chapter 6. 
In Chapter 7, we applied SRU technology for imaging the VV in the rabbit AP and 
validated the imaging results by histology and µCT imaging. A study protocol including imaging 
and validation process is introduced for further extended studies using larger group of animals in 
the future. 
In Chapter 8, we summarize the outcome of the studies presented in this dissertation and 






2.0 Two-dimensional Ultrasound Tracking of the Acoustically Actuated Microswimmers 
The work presented in this chapter was reprinted from Q. Chen, F.-W. F.-W. Liu, Z. Xiao, N. 
Sharma, S. K. S. K. Cho, and K. Kim, “Ultrasound Tracking of the Acoustically Actuated Microswimmer,” 
IEEE Trans. Biomed. Eng., vol. 66, no. 11, pp. 1–1, 2019, doi: 10.1109/TBME.2019.2902523, with the 
permission of IEEE Publishing. © 2019 AIP. 
2.1 Introduction 
2.1.1 Propulsion Mechanism of the Acoustically Actuated Microswimmer 
Among variety of the microswimmer propulsion principles, acoustic propulsion is a 
promising and appealing approach, because it is noninvasive and biocompatible, and largely 
medium independent [30]–[32]. Acoustic waves can travel through biological tissues to perform 
wireless actuations on microswimmers. Moreover, it would be a convenient and economic 
approach if translating into clinical practice.  
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Figure 1 Flow field of the designed one-channel microswimmer by particle tracking velocimetry 
measurement. (Reprinted with permission from ref. [33]. Copyright 2006 IOP Publishing Ltd) 
The principle of acoustic propulsion is first introduced by Dijkink et al, based on the fluid 
mechanical fact that if the Reynolds number is not too small, the fluid intake and discharge from 
the small tube is asymmetric [33]. The asymmetric flow creates a jet that propels the main body 
of the microswimmer in the direction opposite to the outgoing direction of the opening of 
microtubes. Figure 1 shows the flow field of the designed one-channel microswimmer, obtained 
from particle tracking velocimetry data, during the fluid intake and discharge [33]. When a 
microswimmer is immersed into water, a gaseous bubble can be trapped in the cavity due to 
hydrophobicity of the cavity surface. Acoustic wave induces periodical oscillation of a gaseous 
bubble and this oscillating motion in fluid generates force when the bubble is confined in a one-
end-open tube. The oscillation of the gas-liquid interface draws the surrounding liquid from the 
sides and ejects it in the outgoing direction as shown in Figure 1 [33]. The back-and-forth motion 
of the gas-liquid interface results in a non-zero time-averaged flow field around the outlet of the 
tube, by which the miroswimmer is propelled. According to the literature, propulsion force from 
the bubble oscillation has the following formula [36]. 
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          𝐹 = 0.8𝜌𝐴(𝑎𝑓)2                    (2-1) 
In the equation (1), F is the propulsion force. A is the cross-sectional area of the tube opening. 𝜌 
is the density of fluid. f and a represent oscillating frequency and amplitude. Oscillating amplitude 
increases as the acoustic pressure on the drone increases. Note that, the oscillating amplitude is 
maximized when the frequency reaches the resonant frequency of bubbles. The resonant frequency 
of the cavity in the tube is calculated as  






                         (2-2) 
It reveals that in the same condition, resonant frequency is related to the length of water column 
between the bubble interface and the channel opening (𝐿0), and the length of the bubble(𝐿𝐵) 
(Figure 2) [33]. Based on this theory, the oscillation of the gas bubble, therefore the propulsion of 
the microswimmer can be maneuvered by adjusting the actuation frequency and amplitude. 
 
Figure 2 Illustration of the parameters of the microtube in the microswimmer. (Reprinted with permission 
from ref. [33]. Copyright 2006 IOP Publishing Ltd) 
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In earlier studies, the proof-of-concept of the acoustically actuated microswimmer has been 
successfully demonstrated using micro-fabricating by several groups [17], [33], [34].  
Subsequently, it has been shown that the bubble-based microswimmer can be selectively activated 
by tuning the applied acoustic wave frequencies to the resonant frequencies of individual cavities 
and travel in viscous fluid under acoustic actuation[35]. Two dimensional steering and propulsion 
was also realized by adding multiple orthogonally aligned microtubes with different lengths on the 
body of microswimmer [36]. Moreover, a microswimmer with armored microbubbles that showed 
a delayed dissolution and a longer operating life was designed and fabricated[30]. Based on the 
bubble oscillation principle, a miniaturized endoscope with arrays of cavities, which can adjust the 
imaging angles under remote acoustic actuation, has been designed and tested  in vivo[54].  
2.1.2 Tracking of the Acoustically Actuate Microswimmer 
Although acoustic actuation is promising, there is still a long way towards eventual 
translation of the microswimmer technology into biomedical applications. One of the challenges 
is to track the microswimmers while they are actuated to perform tasks inside human bodies. A 
robust tracking strategy available for in situ applications is particularly required in order to locate 
the microswimmers in real-time and provide feedback for accurate control. There has been a lack 
of studies that focus on developing appropriate tracking strategies for biomedical applications of 
the microswimmers. Most of the studies use a camera to record the motion of microswimmers[17], 
[35], [36]. However, optical imaging is not accessible when the microswimmers are injected into 
the human body due to its short imaging depth in tissues. Ultrasound imaging is an adequate 
candidate for tracking the miroswimmers in the biomedical environments. Ultrasound imaging can 
provide larger imaging depth which overcomes the drawbacks of optical imaging. Based on the 
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design of the microswimmer, high ultrasound contrast can be provided, especially from the cavity 
with gaseous bubbles encapsulated. Thus, the location of the microswimmer can be identified with 
high sensitivity, which contributes to the robustness of the tracking. Overall, ultrasound imaging 
is advantageous with  a reasonable spatial and temporal resolution, deep accessibility, as well as 
safety and low cost [3]. Moreover, ultrasound tracking is compatible with the acoustic actuation 
method, which is appealing for combining the propulsion and tracking sequence using the same 
acoustic sensor in the future. 
In this chapter, we demonstrate the proof-of-concept of ultrasound tracking of the 
acoustically actuated microswimmer, for the first time to the best of our knowledge, by comparing 
with the synchronously operated camera tracking in the two-dimensional (2-D) setup in benchtop 
experiments. A laboratory developed tracking algorithm is used to estimate the moving trajectory 
of the microswimmer captured by both imaging approaches of ultrasound and camera for 
comparison. The tracking performance is evaluated on a few typical moving trajectories including 
straight, instantaneous change in direction, and continuous change in direction like a circular 
motion that are realized by two different microswimmer designs. 
2.2 Materials and Methods 
2.2.1 Fabrication and Design of the Microswimmers 
The microswimmers are fabricated by Nanoscribe Photonic Professional system (GT, 
Germany), a 3D laser printer utilizing two-photon polymerization. By creating hollow microtubes 
in the microswimmer, the tubes will automatically entrap air inside themselves due to the 
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hydrophobicity of the material when the microswimmer is being submerged in fluid. Further, tubes 
with different lengths can be selectively activated at their own resonance frequencies, thus 
manipulating the direction of the propulsion. 
The following two designs of microswimmer are applied in the experiment, which perform 
(1) linear and (2) bi-directional motion respectively. The first one (Figure 3a) has single microtube 
passing through its geometric center, thus propelling the microswimmer straight along its axis. The 
microtube has a diameter of 100 μm and a length of 760 μm. In the opening section, the diameter 
is suddenly reduced to 80 μm over the length of 60 μm in order to lock the position of the air-water 
interface via surface tension. This ensures the consistent and desired bubble length through the 
whole experiment. A continuous waveform (CW) electrical signal of 13Vpp at 9.4 kHz is applied 
to the piezo-ceramic actuator for an optimal propulsion of this microswimmer. The second 
microswimmer (Figure 3b) has an additional microtube on each short side of the microswimmer, 
which is orthogonal to the one at the center. This side microtubes provide propulsion in the 
orthogonal direction, which enables turning the microswimmer. The bi-directional microswimmer 
has an 860 μm long center microtube with an 80 μm long neck and the 370 μm long side tube with 
30 μm neck. A CW burst signal of 8.3 kHz, 18 Vpp is applied to the actuator to propel both two 
types of tubes. Due to the difference in length of the tubes, the air cavities inside oscillate with 
different amplitude in response to the same acoustic signal, resulting in different propulsion forces 




Figure 3 (a) Microswimmer design 1 with a single microtube (100 μm in diameter and 760 μm in length). (b) 
Microswimmer design 2 with center (860 μm in length) and side (370 μm in length) microtubes. (Courtesy of 
Dr. Sung Kwon Cho Lab) 
 
2.2.2 Experiment Setup  
The experimental setup is shown in Figure 4. The microswimmer is placed at the bottom 
of the acrylic water tank. A piezo-ceramic actuator glued to the outer surface of the water tank is 
utilized to generate the acoustic field that oscillates the air cavity, therefore propels the 
microswimmer. A CW electrical signal is generated by the function generator 1 (Agilent 33250A) 
through an amplifier (Trek PZD700A) to the actuator. A camera (Phantom V9.1) and two 
commercial ultrasound linear array transducers (L7-4, ATL) connected to a programmable 
ultrasound system (V1 and Vantage, Verasonics, Redmond, WA) are synchronized by the external 
trigger from function generator 2 (Agilent 33250A) to concurrently record the moving trajectory 
of the microswimmer both optically and ultrasonically. Since one-dimensional (1-D) ultrasound 
array transducer from the top of the water surface captures only a cross-sectional image along the 
ultrasound beam direction (axial-lateral coordinates), two ultrasound probes are used to 
complement each other for capturing the full two-dimensional motion of the microswimmer that 
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moves along the bottom surface of the tank (x-y coordinates, see Figure 5). Each ultrasound probe 
is responsible for tracking the motion along the direction of its lateral axis. Two ultrasound probes 
are immersed in water at 30 degrees with respect to the water surface on each side of the camera 
(see Figure 4) and are positioned orthogonal to each other to provide each component of 2-D 
trajectory (x-y coordinates) respectively. The intention of this unconventional placement is to 
avoid blocking the light source for optical imaging, and more importantly, to extend the ultrasound 
elevational field of view for microswimmers (see Figure 5). The reflecting objects located within 
the beamwidth of the probe can be identified and reconstructed at the center line of the elevation 
beam by the ultrasound device [55]–[58]. By tilting the probe in elevational direction, the elevation 
beam area is extended so that the microswimmer moving two dimensionally at the bottom of the 
water tank can be tracked in a large field of view. Only the  motion information along lateral axis 
is used because of the potential artifact along elevation axis that is attributed to the varied intensity 
along the elevation axis from the beam center line [55]. The elevation beamwidth projected on the 
motion plane of the microswimmer is measured to be 7.11mm. To align the camera field of view 
with the ultrasound imaging planes, a microswimmer is first placed at the center of the camera 
field of view. Then, the relative position of the two ultrasound probes is adjusted until ultrasound 
echo from the microswimmer becomes maximum. As a result, the imaging field of view of the 
camera and ultrasound probes are set to overlap at a 6.16 X 6.16 mm2 area of interest (Figure 5). 
The frame rate of recording is set to 30 frames per second for both tracking methods.   
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Figure 4 (a) Experiment schematic. The microswimmer in the water tank is activated by the acoustic actuator 
glued on the water tank with CW electrical signals transmitted by function generator 1 through the amplifier. 
Two ultrasound linear array probes (L7-4) and a high speed camera (Phantom v9.1) are utilized to record the 
movement of the microswimmer simultaneously. Probe 1 and Probe 2 are connected to two separate 
programmable ultrasound scanners (Verasonic V1 and Verasonic Vantage, respectively). The two ultrasound 
probes are immersed in water at 30 degrees to the water surface. Function generator 2 is utilized to transmit 




Figure 5 Imaging field of view. The imaging field of view of each ultrasound probes is 7.11mm (elevation 
direction) X 36.2mm (lateral direction). The imaging field of view of the camera is 6.16 X 6.16mm with 656 X 
656 pixels. The resulting imaging field of view overlaps at a 6.16 X 6.16mm area of interest. 
2.2.3 Tracking Algorithm for Camera and Ultrasound 
A tracking algorithm is developed for assessing the motion information of the 
microswimmer, such as displacement and direction, from which the trajectory is reconstructed. 
The program is written in Matlab (Mathworks, Natick, MA) and applied to both ultrasound and 
camera video and the reconstructed trajectories from each imaging method are compared to each 
other. In the preconditioning procedure of the tracking algorithm, median filter is first applied to 
the images of all frames to minimize any salt-and-pepper noise. Then, the video frames are 
converted to the binary images by applying a threshold. Afterwards, the microswimmer surface 
area is identified in the binary image and the geometrical center of the area is determined to 
represent the position of the microswimmer in each frame. For camera tracking, in each frame the 
displacement in x-y coordinates is calculated by comparing the geometrical center with that in the 
first frame. For ultrasound tracking, the tracking algorithm described above is applied to each 
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ultrasound video acquired by each ultrasound probe to estimate the geometrical center in lateral 
direction. The displacements in x coordinate (lateral direction of probe 1) and y coordinate (lateral 
direction of probe 2) are determined by comparing the geometrical centers in lateral direction with 
those in the first frames in two videos respectively and are then reconstructed into a complete 2-D 
x-y trajectory. 
2.3 Results and Discussion 
Due to strong acoustic back scattering from the microswimmer body surface and the 
gaseous microtube, a relatively clear image of the microswimmer with high contrast was shown 
by ultrasound imaging. 
In Figure 6, each row depicts the superimposed time-lapse image from each event of the 
microswimmer acquired by both camera and ultrasound. Event 1 and Event 2 present the 
movement of the single-tube microswimmer (linear motion). The single-tube microswimmer 
(Figure 3a) is designed to move in a straight line under the acoustic actuation at the resonance 
frequency (9.4 kHz). However, due to the uneven friction at the bottom of the tank surface, the 
trajectory of the microswimmer slightly deviates at some location.  Event 1 in Figure 6 shows that 
the first microswimmer (single microtube) travels straight from the lower-left corner to the upper-
right corner. Event 2 in Figure 6 shows the first microswimmer (single microtube) making a sharp 
turn when experiencing strong uneven friction from the bottom surface of the water tank. Event 3 
in Figure 6 demonstrates the second microswimmer (bi-directional motion) making a circular 
movement. The yellow dashed rectangles in the ultrasound images denote the region of interest 
corresponding to camera images.  
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As shown in Figure 6, a very high contrast of the microswimmer in ultrasound image 
allows for accurate and robust tracking. However, the appearance of the microswimmer in shape 
and brightness varies in the ultrasound image as the orientation of the microswimmer to the 
ultrasound probe changes. This is mainly attributed to the rectangular shape and nonuniform 
ultrasound contrast over the body of microswimmer. In one occasion, the microswimmer appears 
to be a single bright spot because of the strong reflection of the air cavity inside the microtube 
when the microtube is parallel to the lateral axis of the ultrasound probe. In other occasion when 
the microswimmer rotates, the single bright spot splits into two, most likely when the echoes from 
the two short edges of the microswimmer dominate. Thus, all the bright spots nearby within the 
size of microswimmer in ultrasound image are are taken and the geometrical center of them is 
determined as the reference point in the tracking algorithm. In this way, any potential error in 
locating the microswimmer caused by microswimmer body rotation can be avoided. Note that 
while the displacement in axial direction from the ultrasound probe can also be used to reconstruct 
the travel trajectory, because variation of beam intensity over the elevation axis of the ultrasound 
probe can be significant [55], the motion information along the axial displacement is less reliable. 
Thus, the lateral displacements acquire by two ultrasound probes are used to track the motion of 
microswimmers in this study. In Figure 6, the lateral direction of ultrasound probes 1 and 2 are 
labeled in red and blue respectively, which refers to y and x coordinates in the moving plane of 
the microswimmer and are in accordance with the coordinates marked in the camera image. 
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Figure 6 Superimposed time-lapse images from three different events of the microswimmers acquired by both 
camera and ultrasound probes. Figure. 6a, 6b, 6c are the superimposed time-lapse images for a straight type 
motion of the single-tube microswimmer acquired by camera, ultrasound probe 1 and probe 2 respectively. 
Figure. 6d, 6e, 6f show the microswimmer motion with a sharp turn. Figure. 6g, 6h, 6i show the circular 
movement of the second microswimmer by camera and two ultrasound probes. The yellow dashed rectangles 
in Figure. 6b, 6c, 6e, 6f, 6h, 6i denote to the camera images. 
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In Figure 7, in each row the reconstructed trajectory and the error of each event are shown. 
The trajectory by ultrasound tracking shown in the first column is reconstructed by the lateral 
displacement from each ultrasound image: lateral displacement from probe 1 corresponds to y axis; 
lateral displacement from probe 2 corresponds to x axis. For all three events, the trajectory by 
ultrasound tracking is in good agreement with the trajectory by the camera. The second column 
shows the error (E) of ultrasound tracking, which is defined by the discrepancy in the positions 
between ultrasound and camera trajectory at each frame. The error remains within ultrasound 
lateral resolution (~0.3 mm) except one frame in Figue 7h, which assures that the method is 
reasonable and acceptable. Overall, the error of ultrasound tracking is considered mainly to be 
attributed to the relatively low spatial resolution of operating ultrasound frequency. Moreover, it 
is noted that the error becomes larger as the microswimmer rotates. This must be due to the fact 
that the shape of the ultrasound image of the microswimmer changes as its orientation to the 
ultrasound probe changes. In Figure 7h, a few peaks indicate transiently increased errors when the 
microswimmer undergoes rotational motions. Due to the limited spatial resolution, ultrasound 
tracking is not able to identify the rotational information of the microswimmers. In addition, the 
tracking error can also be attributed to the relatively low signal to noise ratio especially when the 
microswimmer is located off the imaging center plane in the elevational direction. Column 3 shows 
the error (E) at each frame normalized to the total moving distance (𝑠 = √∑ (∆𝑥)2 + (∆𝑦)2𝑡0 ) by 
that frame. It is noted that the error between ultrasound and camera tracking does not accumulate 
as the microswimmer travels. It therefore can be expected that when the microswimmer travels a 
quite long distance, the error of this ultrasound tracking approach stays low over the entire course 
of travel. In summary, the ultrasound tracking method demonstrates a good accuracy and 
robustness for three different types of moving trajectories in the benchtop experiments. Taking full 
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advantage of ultrasound in general such as noninvasiveness and capability of imaging through 
tissues, real-time ultrasound tracking and control of the microswimmer in biomedical applications 
in vivo holds a promise. 
There is still room to further improve the ultrasound tracking for the acoustically-actuated 
microswimmers. According to the experiment results, the main limitation of this ultrasound 
tracking approach includes that the error can be relatively large when the microswimmer rotates, 
and this approach is not able to detect the angular change of the microswimmer, which is an 
essential information required for developing a control system for future biomedical application 
of the microswimmer. Applying a state estimator can be a potential approach to improve the 
ultrasound tracking results. The estimator corrects the ultrasound tracking results by using 
predictions from a dynamic model of the microswimmer. Using this estimator, accuracy of the 
ultrasound tracking can be improved to match the true trajectory [59]. In addition, the rotational 
information can be distinguished by means of optimizing the design of microswimmer. Some 
structures with high ultrasound contrast could be incorporated into the microswimmer to label its 
orientation. In the meantime, the tracking algorithm is required to be further revised and improved. 
As the feasibility of ultrasound tracking was validated in this study, future steps will be further 
extending the tracking strategy in a three-dimensional (3-D) setup, which fit more for the real 
clinical applications that the microswimmer travels three-dimensionally inside the human body.  
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Figure 7 Reconstructed trajectory and error analysis of ultrasound tracking for the three different events. 
Figure 7a, 7d, g show the 2-D reconstructed trajectory of the microswimmer from camera and ultrasound 
imaging. Figure 7b, 7e, 7h demonstrates the error (E) of ultrasound tracking compared to camera tracking 
(discrepancy between ultrasound and camera trajectory) at each frame. Figure 7b, 7e, 7h show the error (E) 
of ultrasound tracking normalized to moving distance (𝒔 = √∑ (∆𝒙)𝟐 + (∆𝒚)𝟐𝒕𝟎  ) at each frame. 
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2.4 Conclusions 
In this chapter, we present the ultrasound tracking strategy for the acoustically actuated 
bubble-based microswimmers. A benchtop experiment was conducted to compare the tracking 
results on three typical 2-D motion patterns acquired by synchronized camera and ultrasound 
tracking. The results overall indicate that ultrasound tracking is accurate and reliable to track the 
motion of the microswimmer. Thus, ultrasound tracking can be considered as a promising 
approach to track the motion of the microswimmer in biomedical applications. As the first step, 
this proof-of-concept study built a foundation for the development of a complete tracking system 
for 3-D motion that will work for practical biomedical environments, and the future clinical 
translations of this technology.  
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3.0 3-D ultrasound Tracking of the Acoustically Actuated Microswimmers 
3.1 Introduction 
A robust tracking ability is indispensable for the in vivo applications and clinical translation 
of the microswimmers. In Chapter two, the proof-of concept of ultrasound tracking of acoustically 
activated swimmers was validated by assessing the accuracy and reliability of ultrasound tracking 
through in vitro experiments using the microswimmer that travels in various 2-D trajectories. 
However, it should be considered that in future biomedical applications the microswimmer will 
travel three-dimensionally inside the human body to perform tasks. Therefore, the system that is 
able to track the microswimmer in 3-D is particularly required. In this chapter, we present our 
further developed ultrasound tracking system that can track the arbitrary 3-D motion of the 3-D 
microswimmers, which was designed and fabricated by our collaborating group [60], in real-time. 
The tracking accuracy was evaluated in an in vitro experiment by comparing the results to the 
trajectory recorded by the camera. 
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3.2 Materials and Methods 
3.2.1 Design of the 3-D Microswimmer 
Figure 8 shows the design of the microswimmer that is able to move in three dimensions 
[60]. To navigate in 3-D space, three types of microtubes, “Lateral 1” (890 μm long × 2), “Lateral 
2” (590 μm long × 3), and “Vertical” (470 μm long × 6), are placed in different orientations and 
positions inside the microswimmer body. The individual resonanct frequencies of the microtubes 
were 5.9 kHz, 7.9 kHz, and 11.7 kHz, respectively. A decrease in diameter near the tube opening 
introduces a physical barrier to fix the interface of the bubble and thus maintains its length during 
bubble trapping and operation [61]. As the propulsion direction is opposite to the outgoing 
direction of the opening of microtubes, 3-D propulsion can be achieved by solely or jointly 
actuating the microtubes: (1) propelling upward by Vertical, (2) yawing clockwise or 
counterclockwise by Lateral 1 or 2 respectively, (3) moving forward by Lateral 1 and 2 
simultaneously at 6.3 kHz and (4) downward by gravity. The opening of Vertical tubes is placed 
above the bottom of the microswimmer to have a room to develop microstreaming flow for stable 
taking off/landing on the bottom surface. In addition, a dummy empty tube with both ends open in 
the top corner is intentionally added to reduce the mass in the upper part of the miroswimmer. 
 27 
 
Figure 8 The design of 3-D microswimmer with the overall view (left) and the front view (right). (Courtesy of 
Dr. Sung Kwon Cho Lab) 
3.2.2 3-D Ultrasound Tracking System 
The Figure 9 presents the schematic of the system designed (a) and the experiment setup 
picture (b) for 3-D ultrasound tracking of the microswimmer. The 3-D microswimmer is placed in 
water-glycerin solution (1:10) in the water tank, actuated by the acoustic actuator. The density of 
the solution is close to the density of the 3-D microswimmer, which creates a neutral buoyancy, 
so that the microswimmer can be actuated easier in the vertical direction. For the moving trajectory 
presented in this work, the microswimmer was activated by the piezo-ceramic actuator with 
continuous waveform signal of 99 Vpp at 10.7 kHz. Two ultrasound probes were operated by a 
programmable ultrasound system (Vantage256, Verasonics, Redmond, WA) simultaneously to 
image the microswimmer through the acrylic wall of the water tank. At the beginning of the 
experiment, the microswimmer was placed in the overlaps of the elevation beams of the two probes 
to assure it is seen by both probes. Ultrasound plane wave imaging is utilized to capture the 
locations of the microswimmer. Any motion in axial and lateral directions within the field of view 
can be tracked by the two probes from their initial positions. When the microswimmer moves 
along the elevational direction, the probes are driven by the step motor along the elevational axis 
together with the microswimmer to keep the microswimmer inside the ultrasound field of view at 
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all time. The ultrasound images of each frame from the two probes are transferred real-time to a 
Matlab external function with the control algorithm. The control algorithm senses the elevational 
motion of the microswimmer and sends the control commands to the step motor controller. The 
high-speed camera (PL-D732CU-T, Pixelink, Rochester, NY) is also held at the certain location 
on the step motor, by which the focus overlaps with the ultrasound imaging plane, and is driven 
by the motor with the same command along the elevational axis to track the microswimmer 
simultaneously. The trajectories of the microswimmer are reconstructed from the videos recorded 
by both ultrasound and camera acquisition using the algorithm described in Chapter 2 to evaluate 
the tracking accuracy. The whole system including ultrasound and camera system will be 
synchronized by the external trigger from a function generator (Agilent 33250A). The frame rate 
of the image acquisition is 20Hz. The image data transfer, calculation in the control algorithm, and 
the motor motion are executed within the time between every two ultrasound image frames (0.05 
s) to ensure the real-time availability. 
 
Figure 9 (a) Schematic and (b) picture of the experimental set up. 
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3.2.3 Control Algorithm 
The control algorithm is meant to keep the microswimmer in the intersection area of the 
elevation beams of the two probes all the time during the tracking. The microswimmer is identified 
as a bright spot in the ultrasound image, which contains the pixel with peak intensity. During the 
tracking, two ultrasound images from each probe are transferred to the control algorithm, which is 
embedded in the external function. In the control algorithm, the relative peak pixel intensities of 
the two images, which is the peak intensity of the ultrasound image normalized to the summation 
of the intensity of all pixels, are compared to determine the elevational direction of the swimmer 
motion. Two scenarios (Figure 10) are considered in the control algorithm for operating the step 
motor accordingly. The motor speed is tuned to 2.5 mm/s, based on the typical microswimmer 
moving speed, to ensure that the microswimmer will not be lost outside the overlapped beams 
between two frames. 
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Figure 10 Two scenarios in the control algorithm. 
3.3 Results and Discussion 
In this 3-D tracking system, the microswimmer motion in the lateral-axial (y-z plane as 
noted in Figure 11) coordinate of the ultrasound probe can be captured by ultrasound imaging. As 
the microswimmer moves in elevational (x) direction, the control algorithm determines the moving 
direction and drives the motor that holds the two probes and the camera to follow the 
microswimmer in the elevational direction. Therefore, the motion in y-z plane was captured by 
both camera and ultrasound, while the x-direction motion was roughly represented by the motion 
of the motor. Figure 11 presents the superimposed time-lapse images of the microswimmer in the 
y-z plane acquired by camera and ultrasound. Due to the friction in the fluid, the motion of the 3-
D swimmer can be considered as an arbitrary undetermined motion in response to the acoustic 
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actuation. During the motion, the swimmer was successfully tracked and therefore kept in the field 
of view of both ultrasound probes and the camera at all time, while the probes were being driven 
by the motor to follow the microswimmer motion in the x direction.  
 
Figure 11 Superimposed time-lapse images of the microswimmers acquired by the camera and ultrasound 
probes. 
Figure 12 (a) presents the reconstructed trajectory in the y-z plane from the camera and 
ultrasound tracking using the tracking algorithm described in 2.2.3. It should be noted that both 
the displacement in axial and lateral directions of the ultrasound images acquired by each probe 
can be used to reconstruct the trajectory. Therefore, the trajectories by ultrasound can be derived 
from the frames acquired by either of the probes. In this work, we calculated the displacements by 
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averaging the results from the two probes to minimize the error.  It can be found in Figure 12 (a) 
that the trajectory by ultrasound tracking is in good agreement with the trajectory by the camera. 
The step-motor displacement during the tracking is shown in Figure 12 (b), which corresponds 
roughly to the elevational motion of the microswimmer. The tracking error at each frame, which 
is defined by the discrepancy in the positions between ultrasound and camera trajectory, is shown 
in Figure 12 (c). The tracking errors remain mostly within the ultrasound lateral resolution (~0.3 
mm), which indicate the reliability of the ultrasound tracking. Generally, the tracking error by 
ultrasound is mainly attributed to the relatively low spatial resolution compared to camera. Plane 
wave ultrasound imaging, which can provide a high frame rate with a compromised spatial 
resolution, was used in the tracking sequence in order to ensure the real-time operation. Moreover, 
the tracking accuracy is also sensitive to the orientation of the ultrasound probes. The ultrasound 
imaging planes of the two probes are design to be perpendicular to the x-direction that step motor 
moves. Any angle deviation from the normal will add to the errors in the tracking results. The error 
(E) at each frame normalized to moving distance by that frame remains relatively low as shown 
by Figure 12 (d), which indicates the error does not significantly accumulate as the microswimmer 
travels. In summary, our lab-designed 3-D ultrasound tracking system can accurately track the 
arbitrary motion of the 3-D microswimmer under acoustic actuation. The tracking system is readily 
available for the ex-vivo tissue experiment as the future step towards further translation. 
However, there is still room for further improvement of the 3-D tracking system. Firstly, 
as mentioned above, ultrasound plane wave imaging was used to capture the motion at very high 
frame rate, which compromises the imaging spatial resolution. Compounded plane wave imaging 
with a certain number of transmit angles, which is determined by carefully balancing the trade-off 
between spatial resolution and the frame rate, can be used to reduce the tracking error. As for the 
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orientation of the probes that may affect tracking accuracy, a custom-designed probe holder that 
fix the relative location of the two probes and the step motor is suggested for future ex-vivo and 
in vivo experiments. For potential improvement of the lateral tracking accuracy, an ultrasound 
probe with finer pitch in lateral direction would be appealing.    
 
Figure 12 (a) Reconstructed trajectories in y-z plane by camera and ultrasound. (b) Step-motor displacement 
in elevational direction. (c) Error (E) of ultrasound tracking compared to camera tracking (discrepancy 
between ultrasound and camera trajectory) at each frame. (d) Error (E) of ultrasound tracking normalized to 
moving distance (𝒔 = √∑ (∆𝒙)𝟐 + (∆𝒚)𝟐𝒕𝟎  ) at each frame. 
Regarding the future directions, evaluating the 3-D ultrasound tracking of the 
microswimemr motion in ex-vivo animal tissues, such as porcine eyeball cavity, is expected. This 
would be a preliminary test for one of the potential applications of the microswimmer that 
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navigates through the eyeball cavity towards the retina to deliver drugs. In this work, to provide 
an arbitrary moving trajectory, the trajectory of the 3-D microswimmer is not pre-designed and 
controlled. In the future, a feedback control algorithm would be added when it is ready to maneuver 
the motion of the microswimmer in the desired trajectory by adjusting the actuation frequency and 
amplitude based on the feedback from the ultrasound tracking. Therefore, the experiment with 
more controlled 3-D propulsion and tracking can be envisioned.  
3.4 Conclusions 
In the work presented in this chapter, we propose the 3-D ultrasound tracking system using 
two clinical ultrasound probes that were translated by the step motors. The performance of the 3-
D tracking system was evaluated in a benchtop experiment by tracking the arbitrary motion of the 
newly designed 3-D microswimmer. The results demonstrate that the ultrasound tracking system 
is able to capture the arbitrary 3-D motion of the microswimmer at all time and exhibits a relatively 
high accuracy when compared to the trajectory recorded by the camera. Thus, our designed 
tracking system could be a potential approach for tracking the 3-D microswimmer motion in 




4.0 SRU Imaging: In Vitro Validation of the Spatial Resolution 
4.1 Introduction 
The spatial resolution of conventional ultrasound imaging methods is inherently limited by 
the acoustic diffraction limit of half of the pulse length, which means that two targets located closer 
than the acoustic diffraction limit cannot be differentiated by ultrasound imaging. Inspired by the 
optical super-resolution imaging techniques [47]–[49], SRU imaging was introduced [38]–[41], 
[62] for noninvasive imaging of microvasculature with the spatial resolution beyond the acoustic 
diffraction limit. Figure 13 illustrates the overall block diagram of the SRU imaging technique 
[63]. The basic idea of the SRU imaging is to locate the centroid of each spatially isolated 
microbubbles that are injected and travel through the vascular network over stacks of acquired 
frames. Then the location information of the microbubbles from all the frames are summed up to 
form the complete vascular network with sub-wavelength precision. By this approach, spatial 
resolution can theoretically be improved up to one tenth of the wavelength [38]. In general, the 
key technical component for implement the SRU imaging consists several state-of-art techniques, 
including ultrasound contrast agents that enhance hyperechoic contrast, ultrafast frame rate 
imaging [50], advanced clutter filtering technique that can extracts signals only from microbubbles 
circulating in the vessels with low flow rate and moderate tissue motion[51], and novel 
microbubble center localization techniques that pinpoint the center of each microbubble from the 
extracted signals [38], [42], [43], [48], [49].  
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Figure 13 An illustration of the concept of the SRU imaging technique. (Reprinted with permission from ref. 
[63]. Copyright 2015 Springer Nature) 
However, one drawback of the conventional SRU imaging approaches that utilizes 
microbubble center localization algorithm is the requirement of huge number of frames, since the 
algorithm only locate the centroid of spatially isolated microbubbles, rejecting the signals from 
overcrowded MBs in the process. Typically, tens of thousands of frames corresponding to a scan 
time of several minutes is required to reconstruct one final SRU image. The long scan time hinders 
the clinical applications, especially under conditions in which the tissue motion is pronounced. To 
shorten the scan time, super-resolution optical fluctuation imaging (SOFI) technique for SRU was 
introduced [44], while the spatial resolution achieved is relatively low compared to center 
localization algorithm. Our group introduced a deconvolution-based SRU imaging technology to 
significantly improve the temporal resolution to <1 second while preserving the spatial resolution 
at the same time [42]. The Richardson-Lucy (RL) deconvolution algorithm used in our SRU 
technique is a non-linear iterative deconvolution method which has been widely used for 
deblurring image with the presence of Poisson distributed noise in astronomy and biomedical 
applications [64]–[67]. By this method, each microbubble location from the clumped microbubble 
signals can be located with predetermined PSF, thus making full use of all the frames and shorten 
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the scan time. In the previous study, our group applied the developed deconvolution-based SRU 
imaging technology for imaging the vasa vasorum in the rabbit atherosclerotic plaque in vivo. The 
temporal resolution of 0.6 seconds was achieved, and the vessel as small as 41 µm was identified 
using a 7.7 MHz linear array transducer in this preliminary test [42]. However, one problem of this 
preliminary study is that there was no proof of the true diameter of the identified smallest vessel, 
which means that the spatial resolution of the proposed technology cannot be concluded. Since 
now, few studies have been performed to validate the spatial resolution of SRU imaging in the 
experiments with ground truth. Therefore, the study to validate the imaging capability especially 
spatial resolution in a rigorous manner is particularly required before proceeding to the systematic 
in vivo animal studies. 
In this chapter, we tested our deconvolution-based SRU imaging algorithm on the custom-
designed microfluidic channels with flowing microbubbles in vitro. The spatial resolution of SRU 
imaging was validated by identifying the two closely located microchannels. 
4.2 Materials and Methods 
4.2.1 Design of the Microfluidic Chip 
The spatial resolution of the deconvolution-based SRU imaging was tested in vitro by 
imaging the vessel mimicking microchannels molded in polydimethylsiloxane (PDMS). The 
design of the custom-made PDMS microfluidic chip (uFluidix Inc., Canada) is shown in Figure 
14 in top (a) and longitudinal view (b). Figure 14(c) is the photo of the chip in top view. A single 
microchannel of 60 x 30 µm from the inlet is separated into two microchannels of 30 x 30 µm 
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toward the outlet with the closest wall-to-wall distance of 30 µm. The size of the chip is 25 × 8 ×6 
mm. Such design was to mimic the microvessels that are located closely within the acoustic 
diffraction limit of one-half wavelength (50 µm at 15.6 MHz). Figure 14(d) shows the microscopy 
image of the microchannels around the bifurcation that is marked by the dotted rectangle in Figure 
14(a). 
 
Figure 14 Design of the microfluidic chip in top view(a) and longitudinal view (b). (c) Photo fo the chip in top 
view. (d) Microscopy image of the microchannels around the bifurcation that marked in the dotted rectangle 
in (a). 
4.2.2 SRU Imaging Protocol 
Lab-made microbubbles (MP1950, 3-5 µm) [68]–[70] at the concentration of 3 × 107 
MBs/mL were injected into the microchannels from the inlet at a constant flow rate of 0.6 µL/h 
using a syringe pump (KDS120, KD Scientific). A 15.6MHz linear array probe (L22-14v, 
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Verasonics, Kirkland, WI) connected to ultrasound system (Vantage 128, Verasonics, Remond, 
WI) was used to image the microchannels from the side of the chip while placed in the water tank 
to access the imaging plane as shown in Figure 14(a). When the microbubbles flow through the 
microchannels steadily, multi-angle US plane wave imaging with five steer angles (-3°, -1.5°, 0°, 
1.5°, 3°) was implemented to collect the radiofrequency (RF) data of 500 frames at an effective 
frame rate of 500 Hz. The acquired raw RF data were processed offline to reconstruct the final 
SRU image. 
4.2.3 SRU Signal Processing Procedure 
The SRU signal processing after ultrasound data acquisition was implemented offline in 
MATLAB (Mathworks, Natick, MA). Figure 15 shows the pipeline of the SRU signal processing 
procedure. The acquired raw RF channel data were beamformed using the delay-and–sum 
algorithm and envelope detected for B-mode processing. The echo signals from microbubbles were 
extracted from envelope-detected B-mode data by a spatio-temporal eigen-based decomposition 
clutter filter (SVD filter) [51]. To determine the optimized higher and lower cutoff of the filter, the 
turning points where the singular value curve appeared to be approximately linear were first 
roughly estimated. Several values around the turning points were chosen as the cutoff to test the 
clutter rejection performance. The cutoff points with best filtering performance were then 
manually selected as the final thresholds. The images containing only microbubble signals were 
then interpolated to an increased pixel precision of 10 µm × 10 µm and deconvolved using RL 
deconvolution algorithm [64]–[66] with the pre-estimated PSF to localize the center of each 
microbubble. The final super-resolution image was achieved by summing up 300 frames of the 
deconvolved data that is corresponding to 0.6 seconds.  
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Figure 15 SRU signal processing pipeline. 
4.3 Results and Discussion 
The conventional B-mode image of the microfluidic channels with flowing microbubbles 
is shown in Figure 16(a). Since the distance between the two separated channels (30 µm) is smaller 
than the acoustic diffraction limit of the operating ultrasound frequency (50 µm: half wavelength 
at 15.6 MHz), the two channels cannot be differentiated and therefore were shown as one thick 
channel. In the reconstructed SRU image, the two channels were successfully separated as two 
microchannels (Figure 16b).  
 
Figure 16 (a) B-mode image of the microfluidic channels. (b) Reconstructed SRU image of the microfluidic 
channels. 
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To examine the capability of separating two closely located microchannels, the (closest) 
wall-to-wall distance between the two channels was estimated by averaging the estimated distance 
between the two channels in the 200 µm long area marked in the white dotted box. Figure 17 shows 
the signal magnitude profile of the two channels in axial direction averaged over 200 µm along the 
channel. At the -6 dB point, the wall-to-wall distance measured 30 ± 7 µm, which is close to the 
real wall-to-wall distance between the two channels according to the design of the microfluidic 
chip.  
 
Figure 17 Axial signal magnitude profile averaged over 200 µm along the channel in the area marked in white 
dotted box in Figure 16(b). 
 
Overall, it is demonstrated that the developed deconvolution-based SRU imaging 
technology can separate and identify the objects located as close as 30 µm using 15.6MHz 
ultrasound. Following the in vitro validation, further in vivo animal studies using SRU imaging 
were undertaken in the next chapter. The microfluidic chip proposed in this study can be used as 
a practical tool for systematically validating the spatial resolution and evaluating the performance 
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of different SRU algorithms. As a next step, a well-designed microfluidic chip with various 
channel sizes and wall-to-wall separation distances is suggested for further systematic evaluation 
of the spatial resolution of different SRU algorithm under different operating frequencies. It should 
be noted that some area of the channels in the SRU image appears to be thicker than the real size. 
This could be due to the localization error of the deconvolution algorithm when the microbubble 
density is too high. A finer control of the perfusion is needed for evenly distributed microbubbles 
in the channels. Since the focus of this study is to demonstrate the capability of SRU for 
differentiate two closely located objects, which is defined as spatial resolution, the discrepancy in 
size would not affect the major finding of this study.  
4.4 Conclusions 
By using the custom-designed microfluidic chip as ground truth, the expected spatial 
resolution of 30 µm of the deconvolution-based SRU imaging was validated in this in vitro 
experiment. This evaluation assured the subsequent in vivo animal studies of SRU. Moreover, the 
use of the microfluidic chip can be a practical approach for the systematic evaluation of the 
imaging capabilities of different SRU algorithms. 
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5.0 SRU Imaging for Noninvasive Assessment of Renal Microvasculature Changes in 
Mouse AKI Model 
The work presented in this chapter was reprinted from Q. Chen, J. Yu, B. M. Rush, S. D. Stocker, 
R. J. Tan, and K. Kim, “Ultrasound super-resolution imaging provides a noninvasive assessment of renal 
microvasculature changes during mouse acute kidney injury,” Kidney Int., vol. 98, no. 2, pp. 355–365, Aug. 
2020, doi: 10.1016/j.kint.2020.02.011, with the permission of Elsevier Publishing. © 2020 Elsevier. 
5.1 Introduction 
AKI is a rapid loss of renal function occurring in up to 20% of hospitalized patients [71]. 
The presence of AKI is associated with both increased immediate hospital mortality and the long-
term development of permanent or CKD and eventually end-stage renal disease. It is well accepted 
that AKI can lead to CKD and this risk is affected by AKI severity, duration, and frequency as 
well as age and presence of CKD or other comorbid conditions [72]–[76]. One proposed 
mechanism for AKI-to-CKD progression is the deterioration of the renal microvasculature after 
initial injury, a process known as microvascular rarefaction. Loss of microvascular density, 
particularly in the peritubular capillaries, has been described in a variety of studies of ischemic 
AKI [77]–[81], as well as in human kidneys that undergo ischemia in the process of transplantation 
[82]. The mechanisms of microvascular rarefaction are still under investigation, but studies have 
implicated endothelial dysfunction and/or apoptosis, as well as altered vascular endothelial growth 
factor (VEGF) secretion [78]. The loss of the microvasculature would lead to the impairment of 
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renal perfusion and therefore a predisposition for acute and chronic ischemic injury [77], [83]–
[85]. However, the diagnostic tools that enable noninvasive and quantitative monitoring of renal 
microvascular changes during AKI-to-CKD progression are still lacking. 
Several diagnostic imaging technologies, including magnetic resonance imaging (MRI) 
[86], [87], micro-computed tomography imaging (μCT) [88], [89], and ultrasound imaging [90]–
[92], have been employed in pre-clinical studies to noninvasively and quantitatively evaluate the 
changes of renal microvasculature and renal perfusion for predicting and monitoring progressive 
kidney disease. However, MRI and CT scans have important limitations when used in humans. 
MRI requires long imaging times and the gadolinium-based contrast has been associated with 
development of nephrogenic systemic fibrosis, a debilitating disease [93]. Meanwhile, the risk of 
contrast-induced nephropathy and exposure to radiation limits the widespread or repeated use of 
enhanced CT scans in patients with kidney disease [94]–[97]. In addition, these imaging systems 
are bulky and costly, especially when used for serial imaging.  
Ultrasound imaging has the advantage of safety, noninvasiveness, portability, affordability 
and ease of use. Several approaches, such as Doppler ultrasound imaging [92] and CEU imaging 
[90], [91], have been explored to diagnose AKI-to-CKD progression in animals and humans. 
However, neither technique provides spatial resolution high enough for assessing microvessels, 
especially in the cortex. This is mainly because of the insufficient sensitivity and the acoustic 
diffraction limit of the operating ultrasound frequency. SRU imaging [37]–[46], is an emerging 
technology that can achieve a high spatial resolution of vasculature beyond the acoustic diffraction 
limit [37]. As demonstrated in Chapter 4, the emerging SRU imaging technology can identify the 
microvessels with spatial resolution up to 30 µm (< λ/3), significantly outperforming conventional 
US approaches. SRU imaging technology has already been tested in vivo on animals for imaging 
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microvessels in different organs, such as brain [38], [98], kidney [43], [44], [52], [99]–[101], 
mouse ear [41], rabbit lymph node [53] and tumor cells  [44]–[46], [102], [103], by different group 
for purpose of demonstrating the technical capability. Unlike iodinated CT contrast, ultrasound 
contrast agents (microbubbles) are not nephrotoxic and are generally safe when given systemically 
[104]–[107]. They are already widely used clinically for left ventricular opacification in cardiac 
echocardiography [106]. In combining high spatial resolution with the benefits of traditional 
ultrasound, SRU has the potential to accurately assess changes of kidney vasculature during the 
progressive kidney disease without harming the subject.   
In this study, we applied SRU imaging technology with high spatio-temporal resolution in 
a mouse ischemia-reperfusion (IRI) kidney injury model to demonstrate its ability to quantitatively 
evaluate the microvasculature during AKI-to-CKD progression. US scan was performed in vivo 
on kidneys at 21 and 42 days after IRI, uninjured contralateral kidneys, as well as sham kidneys. 
We quantitatively assessed the kidneys for changes in size, relative blood volume (rBV), vessel 
density, and vessel tortuosity, based on the reconstructed SRU kidney images. The results from 
US assessment on vessel density was correlated with histological analysis as a gold standard for 
validation.   
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5.2 Materials and Methods 
5.2.1 Mouse Kidney Injury Model 
C57BL/6 mice (Jackson Laboratory cat# 000664, Bar Harbor, ME) were subjected to 
unilateral IRI as previously described [108]. Briefly, mice were anesthetized and placed on a 
heating pad to maintain a 37°C body temperature which was confirmed with continuous rectal 
measurements. Using a ventral incision, the right kidney and its pedicle was isolated and clamped 
with atraumatic surgical clips (#RS-5459, Roboz, Gaithersburg, MD) for 30 minutes. The clip was 
removed and incision closed. The contralateral (left) kidney was not injured and served as an 
internal control. CD31 and all US analysis were performed on contralateral, 21 days post-injury 
and 42 days post-injury kidneys, as well as the sham kidneys from mice that did not undergo 
surgery (n = 5 for each group).  
 
5.2.2 Experiment Protocol 
SRU imaging was performed on the sham kidneys, contralateral kidneys, injured kidneys 
at 21 days post-injury and 42 days post-injury (n = 5 each group) (Figure 18c). Mice were 
anesthetized with isoflurane (2% in 100% O2) for the placement of a microrenathane catheter (MR-
025, Braintree Scientific) in the jugular vein for contrast agent injection. Longer term anesthesia 
was achieved with ketamine (100 mg/kg) / xylazine (10 mg/kg) for the ultrasound procedure. 
Paraspinal fur was shaved for US access (Figure 18b). The SRU imaging sequence was operated 
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by a programmable US system (Vantage 128, Verasonics, Remond, WI) equipped with a 15.6MHz 
linear array US probe (L22-14v, Verasonics, Kirkland, WI). Regular B-mode US imaging was 
used to locate the position and orientation of the US probe, so that the entire mouse kidney in the 
maximum longitudinal axis was viewed in the imaging plane. Then, the position and orientation 
of the US probe was fixed by a probe holder to ensure the stability of the probe throughout the 
data acquisition process. Commercial lipid-shelled microbubbles (Definity, diameter 1- 4 µm, 
Lantheus Medical Imaging, N. Billerica, MA), served as US contrast agents, were diluted with 
phosphate-buffered saline (PBS) to concentration of 10% and intravenously injected with a bolus 
of 0.1 mL through the jugular catheter. About ten seconds post injection, imaging data of 1000 
effective frames were acquired using multi-angle US plane wave imaging with five angles (-3°, -
1.5°, 0°, 1.5°, 3°) for spatial compounding at an effective frame rate of 250Hz for subsequent 
signal processing. The kidneys were imaged without the need for organ exteriorization or skin 
incision. After the US scan, the mouse was euthanized and kidneys harvested for weight 
measurement and histology staining.  
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Figure 18 Experimental design for in vivo ultrasound super-resolution imaging on mouse acute kidney injury 
model. (a) Timeline of the experiment (b) Ischemia-reperfusion injury (IRI) is performed on the right kidney 
to induce the acute kidney injury (AKI). The sham, contralateral, and injured kidneys at 21-days and injured 
kidneys at 42-days post injury (n=5 for each group) were scanned by ultrasound in long axis for ultrasound 
super-resolution (USR) images. The kidneys were excised immediately after the scan for fibrosis analysis and 
immunohistochemistry with CD31 staining focusing on renal vasculature around the corticomedullary 
junction. (c) From the reconstructed USR images of the kidneys, kidney changes including area, vessel 
density, and microvasculature tortuosity were assessed. 
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5.2.3 Histology and Immunohistochemistry 
Formalin-fixed, paraffin-embedded kidney tissue was sectioned at 3 µm thickness in the 
long axis of the kidney at the midsagittal plane, corresponding to the plane of SRU imaging. 
Staining with Masson’s Trichrome and picrosirius red were performed according to 
manufacturer’s instructions (Thermo Fisher, Pittsburgh, PA). For fibrosis quantification, at least 
10 high powered (40X) images were taken in the corticomedullary junction for each slide after 
Masson’s trichrome staining. Large vessels were avoided. A 10x13 grid was then overlaid upon 
each image and the grid intersections containing fibrosis were counted compared to total number 
of intersections. The counter was blinded to identifier and treatment group of the sample being 
viewed. For immunohistochemistry, sections were deparaffinized and hydrated before inactivation 
of endogenous peroxidases with 3% hydrogen peroxide in methanol. After blocking, slides were 
incubated in primary antibody against CD31 (#77699S, Cell Signaling Technology, Danvers, MA) 
overnight. Fluorescent anti-rabbit secondary antibody (Jackson Immunoresearch, West Grove PA) 
was then added for 2 hours prior to imaging on an immunofluorescence microscope. For CD31 
immunostaining, images were photographed in a blinded fashion for each mouse in the study. At 
least 5 low-power (10X) images were obtained which cumulatively covered the entirety of the 
corticomedullary junction on a mid-sagittal section of the kidney. Quantitation was performed 






After RNA isolation with TRIzol reagent (Thermo Fisher, Pittsburgh PA) and reverse 
transcriptase reaction, the cDNA was run in a qRT-PCR reaction with SYBR green in a CFX 
Connect (Biorad, Hercules CA). Forward and reverse primer sequences were 
CCACGTCAGAGAGCAACATCA and TCATCTCTCCTATGTGCTGGCTTT for VEGF, 
AGGCAACAGTGGTTCTCCTG and GACCTCGTGCTCCAGTTAGC for collagen III, and 
CAGCTGAGAGGGAAATCGTG and CGTTGCCAATAGTGATGACC for β-actin. 
5.2.4 SRU Imaging Signal Processing Procedure 
Figure 19 (a) shows the block diagram of the SRU signal processing procedure. The post-
processing algorithm of SRU in this study is similar to that described in 4.2.3, except the rigid 
body motion compensation process that will be described in detail in the following section. The 
representative reconstructed images after the main signal processing steps are shown in Figure 
19(b), 19(c), 19(d), and 14(e). 
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Figure 19 SRU signal processing and image reconstruction procedure. (a) Signal processing block diagram. 
The raw radio frequency channel data was acquired by multi-angle ultrasound plane wave imaging and went 
through B-mode processing with delay-and-sum beamforming algorithm and quadrature demodulator. After 
estimating and compensating the rigid body motion of the kidney caused by respiration, a spatio-temporal 
eigen-based decomposition clutter filter was applied to suppress the signals from tissues and extract the 
signals from the microbubbles. RL deconvolution method was used to localize the center of each 
microbubble. Final SRU image was reconstructed by summing up 300 frames of the localized images. (b) 
Representative image of mouse kidney after B-mode processing. (c) Representative image after applying 
tissue suppressor. (d) Representative SRU image after microbubble center localization and frame summation. 
(e) Final image by overlaying the B-mode and SRU images of the mouse kidney. 
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5.2.5 Rigid Body Motion Estimation and Compensation 
The central concept of super-resolution ultrasound imaging technique is to localize the 
center of the flowing microbubbles based on the system PSF in each image frame after suppressing 
the stationary signals coming from tissues. Then the final microvasculature image is reconstructed 
by summation of the localized microbubbles from these frames. Therefore, the vessel size and 
shape are mainly determined by the temporal distribution of the flowing microbubbles within the 
blood vessels. If the respiratory motion occurs, the distribution of the microbubbles will change as 
the vessels displace with the respiratory motion, which will lead to the blurriness of the images 
and, therefore, the overestimation of the vessel size. Figure 20 shows the conceptual schematic 
diagram of the blurred vessel image due to the respiratory motion artifact and its correction during 
the inhalation phase. Thus, it is expected that the spatial resolution and the signal-to-noise ratio 




Figure 20 The schematic diagram of the motion artifacts due to respiration. 
Figure 21 depicts the details of signal processing procedure of the rigid body motion 
compensation algorithm, which was included in the SRU algorithm as shown in Figure 19. First, 
Pearson’s correlation coefficient between the first frame, as the reference frame, and the current 
frame was calculated to determine if any motion was involved. Based on our observations, it is 
determined that the motion can be ignored if the correlation coefficient is larger than or equal to 
0.9975. The respiratory motion compensation technique was applied only to the frames that were 
determined to be decorrelated with the correlation coefficient smaller than 0.9975. Then, the static 
tissues in the images were detected and masked to exclude from the subsequent motion estimation 
process for optimizing the motion estimation performance. The images were divided into the small 
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blocks of 2 mm by 2 mm, and the correlation coefficients of the blocks between each frame and 
the reference frame were calculated. The blocks with the correlation coefficient larger than 0.9975 
were considered as static tissues. Finally, the rigid body motion of the moving organ can be 
estimated by using a 2-D correlation or any traditional block matching algorithms. We arguably 
assumed that the respiratory motion is translational motion with no significant tissue deformation. 
Therefore the resulting displacement is globally estimated, allowing for the phase information of 
I/Q signal unchanged. Here, we chose the three-step search algorithm, which is one of the most 
traditional fast block matching algorithms. This algorithm may not provide the best accuracy but 
still shows a near-optimal performance with the advantage of low computational complexity [109], 
[110]. In the first phase, it searches for the area having the least cost value at neighboring eight 
points with the step size S from the center of the searching block: (+S, +S), (+S, 0), (+S, -S), (0, -
S), (-S, -S), (-S, 0), (-S, +S), (0, +S). Here, the step size S was chosen as 7 mm. The mean absolute 
difference was utilized as a cost function to find the best matching points, 
𝑚𝑒𝑎𝑛 𝑎𝑏𝑠𝑜𝑙𝑢𝑡𝑒 𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒 =  
1
𝑁




𝑖=1                      (5-1) 
where N is searching block size, Cij is the IQ data of the current chosen block, and Rij is the IQ 
data of the reference block. The chosen point was to set the new origin of the searching block, and 
then the iterative searching process continues with half of the step size in the previous phase until 
the current step size becomes 1 pixel. In this way, the motion in the current frame was estimated, 
and the moving organ was shifted back based on the estimated motion vector. Thus, the rigid body 
motion of the organ in each frame was compensated toward the reference frame.  
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Figure 21 Signal processing pipeline of the rigid body motion compensation. 
5.2.6 SRU Image Analysis and Quantitative Assessment of the Microvasculature 
The reconstructed 2-D cross-sectional overlaid SRU and B-mode images of the long-axis 
mouse kidney was used for quantifying changes in kidney size, cortex thickness, rBV, vessel 
density at the corticomedullary junction, and tortuosity of the cortex microvasculature (Figure 
18c). The contour of the kidney was manually selected according to the B-mode layer, by which 
the long axis area of the kidney was determined. In the SRU layer, the vessels were identified by 
threshold-based segmentation. The cortex thickness was determined by the average distance 
between the outer boundary of the kidney and the corticomedullary junction according to the 
vasculature structure depicted in the SRU layer. rBV was calculated as the ratio of vessel area 
inside the kidney to the area of the entire kidney. The vessel density in the area of corticomedullary 
junction was calculated as the ratio of vessel area inside the region of interest (ROI), which was 
selected manually according to the anatomical structure in the SRU image, to the total area of the 
ROI. The analysis above was performed in MATLAB (Mathworks, Natick, MA). The tortuosity 
of the cortical microvasculature was assessed using ImageJ (NIH, Bethesda, MD), with plugin 
Skeletonize3D [111] and AnalyzeSkeleton [112], [113]. 
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5.2.7 Statistical Analysis 
All the quantitative results were presented as mean ± standard error. To evaluate the 
statistical significance, all the data among the four groups (sham, contralateral, 21 days post-injury, 
42 days post-injury, n = 5 each) were compared using one-way analysis of variance (ANOVA) 
with post-hoc Tukey’s Honestly Significant Difference (HSD) Test. The correlation between US 
and histology quantification of the vessel density in ROI was performed using Pearson’s 
correlation analysis. The value of P < 0.05 was considered statistically significant. All the 
statistical analysis and plots are generated using GraphPad Prism 5.0 (San Diego, CA). 
5.3 Results 
Figure 18 presents the experimental design of this study including groups, experimental 
protocol and analysis. 
5.3.1 IRI Leads to the Development of Renal Fibrosis 
Kidneys subjected to IRI in our mouse model exhibited extensive interstitial fibrosis at 
both 21 and 42 days after injury. Masson’s Trichrome stain demonstrated large areas of fibrosis 
only in affected kidneys. Picrosirius red staining confirmed these results, and when these slides 
were viewed under polarized light, collagen fibers specifically exhibited birefringence, confirming 
deposition of extracellular matrix (Figure 22a). Although there was a significant increase in 
fibrosis in the IRI kidneys over contralateral kidneys, we did not find any differences between the 
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21 day and 42 day IRI kidneys (Figure 22b). This suggests that fibrotic development, as assessed 
by our methods, reaches a plateau in our injury model, with timing that is in agreement with 
previously published reports [88]. We confirmed these results with quantitative real-time PCR 
showing that collagen mRNA transcripts are enhanced to similar levels in the 21 and 42 day 
kidneys (Figure 22c). Consistent with previous reports [114], [115], we found that there was a 




Figure 22 IRI leads to renal fibrosis. Mice were subjected to unilateral IRI and both the affected and 
contralateral kidneys were recovered at either 21 or 42 days after injury. (a) Fibrosis was detected with 
Masson’s Trichrome stain (blue staining) as well as picrosirius red stain (dark red). When the picrosirius 
slides were viewed under polarized light, birefringence denotes specific staining for collagens. (b) Fibrosis 
scoring of kidneys. (c-d) mRNA levels of collagen (Col3) are dramatically elevated in all injured kidneys 
compared to the contralateral kidneys. mRNA levels of VEGF are dramatically decreased in all injured 
kidneys. Data are expressed as mean ± standard error. * P < 0.0001 compared to contralateral kidneys, no 
differences were found between the 21 and 42 day injured kidneys. 
5.3.2 In Vivo SRU Imaging Enables a Qualitative Assessment of the Overall Changes of the 
Mouse Kidney with IRI   
Figure 23 depicts the overlaid B-mode and SRU images of sham kidneys (Column A, n = 
5), contralateral uninjured kidneys (Column B, n=5), and the injured kidneys at 21 days (Column 
C, n = 5) and 42 days (Column D, n = 5) after IRI. The 2-D cross-sectional US scan was aimed at 
the center plane of the kidneys in the long axis. The anatomical contour of the kidneys was shown 
from the B-mode layer in gray-scale in the background, and the vascular tree was identified from 
the overlaid SRU images in hot color scale with high spatial resolution resolving microvessels 
down to 32 μm. The major renal vessel branches, aorta, cortex, medulla, and dorsal skin were 
marked by white arrows in the image of the injured kidney from mouse number 6. Although there 
was some interanimal variability, an overall decrease in kidney size and cortical thickness after 
IRI was observed. Of note, obvious rarefaction of the renal vasculature was consistently identified 










Figure 23 Overlaid B-mode and super-resolution ultrasound (B-SRU) images for sham kidneys, contralateral 
kidneys, injured kidneys at 21-days post injury, and injured kidneys at 42-days post injury. Column (a) 
shows the SRU images of the five sham kidneys. Column (b) shows the contralateral kidneys. Column (c) and 
column D show the SRU images of injured kidney scanned at 21 days and 42 days after injury, respectively. 
To provide an anatomical landmark, the major renal vessel branches, aorta, cortex, medulla, and dorsal skin 
were marked by white arrows in the image of the injured kidney from the mouse number 6. Overall decrease 
in size and increase in vasculature rarefaction were observed over time. 
5.3.3 In Vivo SRU Imaging Enables a Quantitative Assessment of the Changes in Overall 
Morphology and Renal Perfusion of the Mouse Kidney with IRI 
Figure 24(a) plots the average of the cross-sectional area in the long axis of the kidney 
measured from US B-mode image, which demonstrated a significant decrease in size in injured 
kidneys of 21 days (37.54 ± 1.55 mm2) and 42 days (35.67 ± 2.41 mm2) compared to sham (49.20 
± 1.58 mm2). This agreed with the measured kidney weights (Figure 24b), which decreased from 
160.50 ± 4.83 g (sham) to 96.94 ± 6.22 g (21 days) and 80.70 ± 6.14 g (42 days). As expected, the 
weight of the contralateral kidney (197.70 ± 8.08 g) was increased compared to sham, consistent 
with compensatory hypertrophy. However, this change was too subtle to observe in cross-sectional 
ultrasound imaging. The areas of the cortex and medulla were manually identified according to the 
structural B-mode and overlaid vasculature images. For sham, contralateral, 21 days and 42 days 
post-injury kidneys, the average thickness of the cortex was estimated to be 1.76 ± 0.03 mm, 
1.88 ± 0.08 mm, 1.23 ± 0.04 mm and 1.10 ± 0.08 mm respectively (Figure 24c), supporting the 
trend of continuous reduction in the kidney size with the progression of kidney injury. There was 
significant decrease of the cortical thickness by comparing 21 days (P < 0.001) and 42 days (P < 
0.001) post injury kidneys to either sham or contralateral. No significant difference was found 
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between 21 days and 42 days post injury. The vessel densities in different regions of interest, 
including the entire kidney, cortex and corticomedullary junction of the kidneys were quantified 
from the SRU images. The rBV, which is defined as the percentage of the blood volume to the 
total organ volume [88], [116], was estimated at 34.66 ± 1.99% in sham, 35.85 ± 1.38% in 
contralateral, 22.35 ± 1.38% in 21 days post injury, and 26.30 ± 1.92% in 42 days post injury 
(Figure 24d). By statistical analysis, a significant decrease between sham and 21 days (P < 0.001), 
and between sham and 42 days (P < 0.05) was demonstrated. The vessel density in the cortex was 
measured to be 64.44 ± 1.80% in sham, 66.96 ± 2.69% in contralateral, 39.77 ± 2.69% in 21 days 
post injury, and 46.47 ± 2.47% in 42 days post injury (Figure 24e). A significant decrease between 
sham and 21 days (P<0.001), and between sham and 42 days (P<0.001) were found. Compared to 
21 days, a slight nonsignificant increase of rBV and vessel density in the cortex at 42 days post 
injury was noted. The vessel density in the corticomedullary junction of the sham, contralateral, 
and in the 21 and 42 days injured kidneys were estimated to be 47.14 ± 2.41%, 49.59 ± 2.42%, 
26.17 ± 1.28% and 27.60 ± 1.37%, respectively (Figure 24f). These densities were obtained by 
calculating the area fraction of the segmented vessels in the region of interest in SRU images of 
the kidneys. The vessel density in the corticomedullary junction of 21 and 42 days post-injury 
kidneys were significantly decreased compared to sham (P<0.001) and contralateral (P<0.001), 
but a significant difference was not found between the two injury groups. SRU demonstrated a 
small nonsignificant increase in vessel density between the sham and contralateral groups. These 
quantitative assessments support prior findings of perfusion impairment chronically after a single 
episode of AKI [88], [90]. 
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Figure 24 Quantitative assessment of the changes in overall morphology and renal blood volume of sham, 
contralateral, and IRI kidneys. (a) Kidney cross-sectional area measured from the long-axis US B-mode 
images. Cross-sectional areas of the sham, contralateral, 21 days post injury and 42 days post injury kidneys 
were 49.20 ± 1.58 mm2, 51.61 ± 3.57 mm2, 37.54 ± 1.55 mm2, 35.67 ± 2.414 mm2. A significant decrease in 
kidney area after IRI was observed by ultrasound measurement. (b) Weight of the sham (160.50 ± 4.83 g), 
contralateral (197.70 ± 8.08 g), and injured kidneys (21 days: 96.94 ± 6.22 g, 42days: 80.70 ± 6.14 g). 
Significant reduction in weight was found, which supports the size decrease measured by US. (c) Cortex 
thickness of the kidneys measured from the US images. Significant decrease of the cortex thickness of the 
injured kidneys (21days: 1.23 ±0.04 mm, 42 days: 1.10 ±0.08 mm) compared to sham (1.76 ±0.03 mm) and 
contralateral (1.88 ±0.08 mm) was found. (d) US estimation of relative blood volume (rBV). The average rBV 
of the sham kidneys, contralateral kidneys, and IRI kidneys at 21 days and 42 days were 34.66% ± 1.99%, 
35.85% ± 1.88%, 22.35% ± 1.38%, and 26.30% ± 1.92%, respectively. Significant decrease of rBV on IRI 
kidney was observed. (e) Vessel density in the cortex measured by US. A significant reduction in 21 days 
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(39.77 ± 2.69%) and 42 days (46.47 ± 2.47%) post-injury kidneys compared to sham (64.44 ± 1.80%) and 
contralateral (66.96 ± 2.66%) kidneys was found. (f) Vessel density in the corticomedullary junction 
measured by US. A significant decrease in 21 days (26.17 ± 1.28%) and 42 days (27.60 ± 1.37%) compared to 
sham (47.14 ± 2.41%) and contralateral (49.59 ± 2.42%) was found. (n=5, ANOVA with post-hoc Tukey HSD 
test, *P<0.05; **P<0.01; ***P<0.001.) 
5.3.4 In Vivo SRU Imaging Correlates with Histology in Vessel Density Estimation 
Figure 25(a) shows CD31 immunostaining of the corticomedullary junction area of the 
sham, contralateral, and IRI kidneys at 21 and 42 days, a region that is particularly susceptible to 
IRI 7. The mean vessel density in the corticomedullary junction from each group, determined as 
the fractional area of staining from a midsagittal slice of the kidney, was 12.14 ± 0.75% for sham 
kidneys, 15.02 ± 0.47% for contralateral, 7.56 ± 0.22% for IRI kidneys 21 days post injury, and 
8.82 ± 0.73% for IRI kidneys 42 days post injury (Figure 25b). Significant reduction of vessel 
density through histologic assessment was demonstrated between sham and 21 days (P < 0.001), 
and between sham and 42 days (P < 0.01). The significant reduction was also found by comparing 
contralateral to 21 days (P < 0.001) and 42 days (P < 0.001). The statistical significance by 
comparing injury groups to sham or contralateral agrees with the US assessment in the same area 
shown in Figure 24(f). Moreover, the vessel density of contralateral was shown to be significantly 
higher than the sham group (P<0.05) by histology, which suggests the compensatory increase in 
blood flow or remodeling induced by the injury on the other side of the kidney. Figure 25(c) 
compares the histology with US assessment of the vessel density in the corticomedullary junction 
on a total of 20 kidneys over four different groups. There was a significant correlation between 
vessel density values determined by histology and SRU in the corticomedullary junction (P < 0.001, 
R2 = 0.77), supporting the accuracy of the microvascular density assessment by SRU imaging. 
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Figure 25 Vessel density in the corticomedullary junction by histology and correlation with US imaging. (a) 
Representative CD31 staining of the sham, contralateral, and IRI kidneys. (b) Vessel density measured as 
positively stained area fraction of the vessels in corticomedullary junction. (Sham: 12.14 ± 0.75%, 
contralateral: 15.02 ± 0.47%, 21 days: 7.56 ± 0.22%, 42 days: 8.82 ± 0.73%) Injured kidneys exhibited a 
decrease of vessel density in the ROI compared either sham or contralateral kidney. (n=5, ANOVA with post-
hoc Tukey HSD test, *P<0.05; **P<0.01; ***P<0.001.) (c) Significant correlation between the histology and 
SRU measurement of the vessel density in the corticomedullary junction was found (P value < 0.001, 
correlation coefficient: 0.77). (n=20, Pearson’s correlation analysis) 
5.3.5 In Vivo SRU Imaging Enables a Quantitative Assessment of the Tortuosity Changes 
in the Cortical Vasculature 
The tortuosity of the cortical microvasculature, which is defined as a ratio of the vessel 
length between two nearby branching points and the linear distance between those, was also 
assessed for each kidney from the four groups. Figure 26(a) shows representative SRU images of 
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the cortical microvasculature from the sham kidney and the kidney at 42 days post-injury. It is 
observed that the more terminal vessels are overall more tortuous and aggregated at 42 days post-
injury, while most vessels have straight branches in the sham group. Figure 26(b) plots the average 
vessel tortuosity of the sham kidneys (1.129 ± 0.016), contralateral kidneys (1.143 ± 0.008), 21 
days post-injury kidneys (1.146 ± 0.017) and 42 days post-injury kidneys (1.194 ± 0.012). A 
significant increase of the tortuosity in 42 days post-injury kidneys was found compared to the 
sham group (P < 0.05). 
 
Figure 26 Tortuosity of the control kidney and IRI kidney. (a) Representative SRU images of the cortical 
vessels from control and 42-days post-injury kidneys are shown. White arrows indicate the curved and 
clamped vessels from 42-days post-injury kidney. (b) Significant increase of cortical microvasculature 








This study shows that SRU imaging is able to visualize renal microvessels with very high 
spatial resolution. The high quality SRU images enable a quantitative assessment of the kidney 
vascular structure in different aspects including rBV, microvascular density and tortuosity during 
AKI- to-CKD progression, all in a noninvasive manner. The results are in agreement with the 
known phenomenon of vascular rarefaction in established mouse kidney IRI models [71], [77], 
[79], [88]. The vessel density measured by SRU correlates well with the histologic measurements, 
demonstrating the robustness of this technology.  
The unilateral IRI mouse model adopted for this study is a well-established model of AKI-
to-CKD progression [108]. In this model, the kidney exhibits a reduction in size over time, along 
with perfusion impairment and microvascular rarefaction. As expected, we demonstrated that this 
is associated with the development of extensive renal fibrosis, as well as a reduction in VEGF 
which would contribute to vessel rarefaction [117]. During the US scan, in order to have consistent 
comparisons, all mouse kidneys were imaged at the center plane in the long axis with same settings 
of the US system, and vessel segmentation threshold was applied at -25dB for all the images. The 
results show that SRU imaging is able to visualize renal microvessels with very high spatial 
resolution. The changes in kidney size, cortex thickness, rBV, microvascular rarefaction, and 
tortuosity were successfully quantified from high quality SRU images and demonstrate progressive 
pathologic changes over time. The close correlation (R2 = 0.77) between the SRU and histology 




The absolute values of the rBV and vessel density from SRU were generally higher than 
those from the histology readings. The discrepancy could be mainly attributed to the finite 
transducer elevational beamwidth (or imaging slice thickness) that is around 1.6mm. The US echo 
signals that originate slightly off-center from the imaging plane but within the elevational 
beamwidth of the transducer will still be recognized by the imaging system and contribute to the 
signal intensity in the final reconstructed images [55]–[58]. Thus, the rBV and vessel density can 
be overestimated by dividing the volumetric vascular signals within the imaging slice thickness by 
the 2-D area. In addition, a relatively low SNR in some areas of the kidney may have affected the 
deconvolution process during image reconstruction [64]–[66], resulting in the overestimation of 
the vessel population. The relatively low SNR may also contribute to the lower sensitivity of SRU 
compared to histology, especially in the area with high vessel density that has already overcrowded 
microbubbles during imaging. Therefore, while kidney weight and vessel density measured with 
histology were significantly higher in the contralateral compared to sham kidneys (consistent with 
reactive changes during unilateral IRI), SRU could not detect this difference with significance. 
The microvessels inside the mouse renal cortex are reported to be as small as several microns. 
Although the spatial resolution of SRU is greatly improved compared to conventional US imaging, 
small arterioles and capillaries as well as venules below the spatial resolution of SRU imaging 
cannot be identified as individual vessels. Thus, the single vessel shown in the SRU images could 
actually represent one or several adjacent smaller vessels under 30 microns. This also might have 
contributed to the slight overestimation in rBV and vessel density measurement. Although these 
minor discrepancies exist, it does not affect our major findings in the correlation between SRU 
and CD31 stain, and the statistical difference between the injured and sham groups. Our overall 
immunohistochemical staining and measurements of vascularity show a similar trend to prior 
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published data [88]. While our sham kidneys have a different percentage area than the prior 
published report, this is likely due to differences in thresholding used in our study. However, the 
same threshold was utilized for every image for consistency in analysis. 
According to our tortuosity analysis, the microvascular tortuosity was significantly 
increased at the late time point of 42 days after IRI, which is in concordance with ex-vivo μCT 
results in an earlier study [88]. This alteration could be a useful index for predicting disease 
progression. It should also be noted that microvessels with high tortuosity will aggregate together 
in a finite area of the kidney. These individual vessels will be more difficult to separate at the later 
stages of injury, which may result in the overestimation of vessel density. This could be the reason 
for the slight increase in cortical vessel density and rBV at 42 days compared to 21 days. It is also 
possible that increases in rBV and vessel density, as a ratio of percentage of blood volume to area, 
are due to the overall loss of kidney and cortical size at the late time point of our study. This trend 
of slight increase of vessel density at 42 days was also found by the histological assessment.  
There are some limitations of this study. Since we aimed in this study to first validate the 
feasibility of SRU technology in this study, the kidneys were harvested for histology after each 
US scan. In the future, a longitudinal monitoring of the kidney by SRU would be helpful to 
minimize interanimal variations and investigate the effects of drug interventions during the 
disease. In addition, the accumulation of the dense microbubbles in cortical blood vessels would 
block ultrasound energy from deeper transmission into the medulla, leading to lower intensity of 
medullary blood vessels and discontinuity in the SRU images. This is especially prevalent in sham 
and contralateral kidneys that have higher cortical vessel density. A carefully selected microbubble 
concentration would be needed to compromise the image quality between the cortex and medulla. 
Moreover, there is still room for further improving the performance of SRU in the future, such as 
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3-D US scan to achieve volumetric information, using US probe with higher frequency to enhance 
the spatial resolution, and advanced signal processing techniques to enhance the SNR and 
sensitivity of SRU. Finally, the reduction in kidney size over time may have affected our 
quantification of vessel density and rBV, but this would have actually led to an overestimation 
since these measurements were adjusted to total tissue area.   
In previous studies by other groups, μCT [88], [89] and CEU [90] were proposed as 
diagnostic methods for noninvasively evaluating progressive kidney disease. In the CEU study 
[90], renal perfusion impairment was detected and quantified noninvasively. The kidney from IRI 
mouse model was scanned in the long axis and the renal cortical perfusion was measured according 
to video intensity, similar to our study design. However, the precise microvascular structure within 
the kidney, especially in the area of the medulla and cortex, cannot be visualized clearly by CEU 
due to its limited spatial resolution and inability to identify ROI with accuracy and consistency. 
For the same reasons, CEU cannot provide detailed information on vessel tortuosity. In the μCT 
studies [88], [89], spatial resolution down to 20 µm voxel size were achieved in vivo allowing the 
quantification of blood volume. However, the in vivo μCT approach still suffers from radiation 
and contrast toxicity issues, which hinders serial monitoring in practical applications. SRU for 
imaging renal microvascular changes has been studied before in a rat IRI model [52]. However, 
that study was performed on limited animal samples and without histological and statistical 
support. In this study, we used increased number of animals and groups in order to determine 
statistical significance.  We have also validated our technology with histologic analysis. Compared 
to other previous imaging methods, SRU imaging provides competitive performance for 
noninvasive visualization and quantification of vessel characteristics. Since it is also safe and 
affordable, SRU is a promising technology to aid in the monitoring and potential prognostication 
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of kidney disease. For instance, in patients who sustain AKI, an assessment of the microvasculature 
could predict the future development of CKD. Microvascular assessment could also aid in the 
understanding of the vascular changes occurring over time in humans with AKI or CKD. Another 
potential application of SRU imaging would be evaluating renal transplants soon after implantation 
into recipients since all renal transplants experience a degree of AKI. The evaluation of their 
microvasculature might be able to predict which kidneys will do well long term and which will 
not.  It should be noted that US microbubbles are widely used in clinics, and have a good safety 
profile [104]–[107]. Translating this technology for human use requires adaptation of the technique 
for the curved array ultrasound probe commonly used in clinical abdominal imaging which 
provides a deeper and wider field of view. While the algorithms used in this study are being 
continually optimized and adapted to the curved probe, it is notable that the technique described 
exactly as in this manuscript can be (and has been) applied with success in humans. In fact, kidney 
imaging in humans is in many ways easier since the size of the kidneys and their blood vessels are 
much larger than in mice. Studies on more human subjects including healthy volunteers and CKD 
patients are ongoing for translating this SRU technology to human clinical use. 
5.5 Conclusions 
In conclusion, we show that SRU imaging is able to identify renal microvessels with 
unprecedented high spatial resolution up to 32 μm in vivo and allow for quantification of the 
changes in kidney morphology and vasculature, including size, rBV, vessel density and tortuosity. 
This was demonstrated in a clinically relevant rodent model of AKI-to-CKD progression. A 
relatively high correlation between SRU and traditional immunohistochemistry of vessel density 
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was found with R2 = 0.76 which validates the accuracy of the quantitative assessment by SRU. 
Therefore, SRU has a great potential to provide key clinical data to aid in the care of patients with 
progressive kidney disease.  
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6.0 SRU Imaging of Human Kidney Imaging Using Clinical Curved Linear Array Probe 
6.1 Introduction 
In the previous chapter, we demonstrated the capability of SRU imaging for noninvasive 
and quantitative evaluation of the microvascular changes after initial AKI using the mouse model. 
For translating the SRU technology into human use in clinics, the SRU algorithm that is adapted 
to human applications and validation of the algorithm on human subjects is required. In most of 
the previous studies, the feasibility of SRU for in vivo kidney vasculature imaging was 
demonstrated on small animals using high frequency linear array transducers. However, for 
imaging the human kidney, a larger imaging depth, as well as a larger imaging field of view is 
required. Therefore, a curved linear array ultrasound probe commonly used in clinical abdominal 
imaging needs to be used. Few studies have been conducted to develop and evaluate SRU 
techniques using a curved array transducer on human subjects.  
In the study of this chapter, we configured the deconvolution-based SRU algorithm on a 
clinical curved linear array transducer and applied the technology on healthy human subjects and 
patients with CKD. The performance of SRU imaging including the image resolution, and the 
capability of identifying the vascular changes between patients and healthy subject, were 
evaluated. 
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6.2 Material and Methods 
6.2.1 Study Approval and Human Subject Recruitment 
This human subject study was approved by Institutional Review Board of University of 
Pittsburgh. All experimental procedures including human subject recruitment and the ultrasound 
scan were performed in accordance with all guidelines and regulations detailed in the protocol. In 
this study, two healthy human subjects and 5 patients with CKD were recruited and scanned at 
University of Pittsburgh Medical Center. Written informed consent was obtained from all 
participants for the ultrasound scan.  
6.2.2 Imaging Protocol 
During the scan, the human subjects were lying in the left lateral recumbent position to 
allow the ultrasound access to the right kidney. A clinical curved linear array probe (C5-2, ATL, 
centered at 3.125 MHz) connected to a programmable ultrasound system (Vantage 128, 
Verasonics, Remond, WI) was used for imaging the entire right kidney in long axis. The scan 
process is implemented by the custom-developed imaging and data acquisition sequence for 
human kidney SRU imaging. Firstly, the live mode multi-angle (-3°, -1.5°, 0°, 1.5°, 3°) ultrasound 
plane wave imaging was used to locate the optimal long axis imaging section of the kidney. A 
bolus of 2mL microbubbles (Definity) at concentration of 13% was intravenously injected over 10 
seconds to the healthy human subject followed by a 10mL saline flush, while the ultrasound probe 
was held at the imaging site. About thirty seconds after injection, the sequence was switched to 
data acquisition mode to collect a total of 2000 consecutive frames (500 frames/s) by the multi-
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angle ultrasound plane wave imaging, while the subject held their breath during this period. The 
acquired raw RF data were post processed to reconstruct the final SRU image in Matlab 
(Mathworks, Natick, MA). 
6.2.3 Adaptation to Curved Linear Array 
6.2.3.1 Imaging Sequence 
During the ultrasound scan on the human subjects, two separate imaging modes are needed: 
1) finding the optimized imaging section of long axis kidney with regular B-mode imaging, and 
2) raw RF data acquisition at a high frame rate plane wave mode. However, breathing motion 
during human imaging, which affects the locations of the kidney in the abdomen significantly, can 
be more critical compared to the experiments on anesthetized animals that the pace of the breath 
is quite consistent. Therefore, we developed a customized imaging sequence for the ultrasound 
platform that combines the two imaging modes into one sequence, so that the time for switching 
the different imaging scripts can be saved and therefore the data acquisition can start as soon as 
the optimized imaging plane is located. The two modes use the same excitation waveform but have 
different frame rate and total number of acquisition frames. Figure 27 shows the user interface of 
the custom-designed sequence by adding the “SRU” button for initiating the data acquisition. The 
imaging sequence started with the regular live B-mode scan for locating the mid-section of long 
axis kidney. Then the probe was held still at the location and the microbubbles were injected, 
during which the subjects were allowed to breathe freely. After about thirty seconds of injection, 
the data acquisition started by turning the start button on, while the subject was asked to hold a 
breath during the time of data acquisition of about 3 seconds. 
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6.2.3.2 Mechanical Index Limit for Safety 
The mechanical index (MI) of the sequence was measured before the implementation on 
human subjects to ensure the safety. The MI is calculated as MI = 
𝑃𝑁𝑃
√𝑓𝑐
, in which 𝑃𝑁𝑃 is the negative 
peak preasure of the transmitted ultrasound wave, and 𝑓𝑐  is the center frequency. The 𝑃𝑁𝑃 of the 
imaging sequence at 40 mm, which is about the average depth of the kidney, is measured to be 
0.438 MPa by hydrophone (HNC, Onda Corp., Sunnyvale, CA). Thus, the MI is estimated to be 
0.25, which is much lower than the limit of 1.9 that is suggested by the Food and Drug 
Administration. Considering the microbubble cavitation by ultrasound insonification, the 
measured number is also far lower than the MI of 1.8 that was reported to cause hemorrhage in 
kidney [118], [119]. 
6.2.3.3 PSF Measurement and Coordinate Transform 
The raw data were processed with delay-and-sum beamforming, spatio-temporal eigen-
based decomposition clutter filter (SVD filter) [51], and RL deconvolution algorithm [64]–[66] 
that was adapted and optimized to the curved array acquisition. The signal processing pipeline 
with the representative images for each step was shown in Figure 28. The final SRU image was 
reconstructed by summation of 300 consecutive frames (corresponding to 0.6 s) with minimized 
physiologic motion artifact. 
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Figure 28 SRU signal processing pipeline for human kidney imaging with representative images for each step. 
 
In the RL deconvolution part, the PSF is determined by the simulation packages provided 
by the ultrasound system (Vantage 128, Verasonics, Remond, WI). For the curved array 
transducer, the diverging beam was transmitted through the tissues. Thus, the size and shape of the 
PSF varies a lot along the lateral directions. Since the data acquisition is line by line by each piezo-
ceramic element, the received RF data structure was stored in a matrix, the same as when using a 
linear array. In this study, we first estimated the PSF and ran the deconvolution as if imaging using 
a linear array transducer. The PSF was measured from the B-mode image reconstructed by the 
simulated RF data with a target at the depth of 60 mm, which is around the center of the kidney. 
After deconvolution and frame summation in the manner of linear array acquisition, the resulting 
line by line signals were transferred into polar coordinate for the final SRU image. 
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6.2.4 Results  
In this study, we scanned a total of 2 healthy human subjects and 5 patients with CKD. The 
analysis on the size, including longitudinal dimension, cortex thickness and cross-sectional area, 
and the vessel density in different areas, including the entire kidney and cortex, were performed 
based on the reconstructed SRU imaging. The results were compared between kidneys from 
healthy subjects and patients with CKD. 
Figure 29 shows the representative B-mode image (a) and overlaid B-SRU image (b) of 
the kidney from a healthy subject. The SRU image of the human kidney vasculature network 
(Figure 29b) in the maximum long axis view was successfully reconstructed with a relatively high 
spatial resolution. Combining the B-mode (Figure 29a) and SRU images (Figure 29b), the overall 
vascular network and individual microvessels in different regions of the kidney, such as 
corticomedullary junction and cortex were identified with high resolution. Figure 29 (c) shows the 
zoomed-in image of the area marked by the yellow dotted rectangles in Figure 29 (b). The smallest 
renal microvessel identified, which is marked by the white solid line in Figure 29(c), was measured 






Figure 29 (a) B-mode image of the human kidney. (b) Overlaid SRU and B-mode images of the kidney. (c) 
Zoomed in SRU image of the ROI indicated by white dashed rectangle in (b), with detectable smallest vessel 
marked by white arrow. (d) Spatial profile of the selected vessel. FWHM is estimated at 0.14 mm (<λ/3). 
Figure 30 presents the overlaid B-SRU images of the kidneys from all seven participants.  
The size reduction of the entire kidney can be found in the CKD kidneys compared to the healthy 
kidneys. Obvious overall vascular rarefaction was observed in the CKD kidneys. The loss of 
smaller vessel at the end of the branches of the major vessels was also identified. The quantitative 
analysis is shown in Table 1, which reveals the reduction in longitudinal dimension, cortex 
thickness and cross-sectional area of CKD kidneys compared to healthy kidneys. Thanks to the 
reconstructed vascular network at high spatial resolution by SRU, quantitative measurement of the 
rBV and vessel density in the cortex can be performed as shown in Table 2. The vascular 
rarefaction of the entire kidney, as well as in the cortex, was evidenced. Overall, the size reduction 
and vascular rarefaction could be found in CKD kidneys by SRU imaging, which agrees with the 
findings in previous studies [77]–[81], although the statistical significance was not performed due 












Table 1 Quantitative measurement of the sizes of the healthy and CKD kidneys 
Longitudinal dimension (mm) Average (mm) 
Healthy 99.1 92.58    95.84 
CKD 77.8 86.69 92.73 73.87 61.9 78.598 
cortex thickness (mm) Average (mm) 
Healthy 12.53 12.93    12.73 
CKD 11.07 12.62 11.21 12.06 9.26 11.244 
Cross-sectional area (mm2) Average (mm2) 
Healthy 4546 4078    4312 
CKD 3745 3654 3942 3600 2849 3558 
 
Table 2 Quantitative measurement of the vessel densities of the healthy and CKD kidneys 
Relative blood volume Average 
Healthy 40.26% 39.63%    39.95% 
CKD 31.17% 34.07% 35.97% 33.31% 35.30% 33.96% 
Vessel density in the cortex Average 
Healthy 53.21% 45.61%    49.41% 
CKD 39.73% 36.25% 38.71% 35.50% 27.95% 35.63% 
 
       
 
6.2.5 Discussion 
In this study, the SRU imaging technology was adapted to the clinical curved linear array 
probe and tested on both healthy human subjects and CDK patients, for which few studies have 
been done before. A good performance was demonstrated for imaging the human renal vascular 
network with a spatial resolution of 0.14 mm, which is smaller than one third of the ultrasound 
wavelength at 3.125 MHz. Through the first in human use study, we demonstrated for the first 
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time the capability of SRU for quantifying differences in microvascular structure between healthy 
and CKD human kidneys, with limited number of subjects. The developed technology and the 
imaging protocol would build a scheme for future extended study with a larger group of subjects. 
CKD is a common problem significantly associated with morbidity and increasing 
prevalence. It is commonly diagnosed and monitored via serum creatinine. However, the staging 
and prognostication precision is limited due to the significant variability with age, race and muscle 
mass [120]. Therefore, the developed SRU imaging that can identify the microvascular changes 
could be a promising alternative for quantification of CKD. The SRU might provide one more 
piece of information that will allow us to determine the severity of CKD in a patient, and whether 
the patient will get worse over time. SRU technology has many other potential applications outside 
of CKD as well. One subject is to identify and monitor the microvascular changes during AKI-to-
CKD progression, an example of which we have already presented in the encouraging results of 
the animal study in Chapter 4. Another area of interest is the renal transplant. Currently the gold 
standard for diagnosing transplant rejection is biopsy of the transplanted kidney. There have been 
several studies showing CEU imaging has promise detecting allograft rejection [121], [122]. With 
the superior spatial resolution compared to the conventional CEU, SRU could be a more 
appropriate tool to avoid invasive biopsies and could lead to safer and more rapid diagnosis of 
transplant rejection.  
This study also has several limitations. Firstly, due to the limited number of subjects, 
especially healthy human subjects, the statistical analysis of the quantitative measurements was 
not performed. The extended and more systematic study with a larger sample size is required to 
determine the SRU capability of the quantitative assessment of human kidney. Concerning the 
imaging technology, the PSF used in the deconvolution process also varies in the axial direction, 
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especially in human kidney imaging since the imaging range in the axial direction is quite 
substantial. An adaptive deconvolution algorithm based on depth dependent PSF is suggested to 
achieve a better accuracy in locating the microbubbles, therefore resulting in a more robust 
reconstruction of the vascular network. It should be noted that all the scans were performed on 
subjects with moderate BMI, by which the kidney is located at a relatively shallower depth. For 
imaging the kidney at deeper locations, the attenuation from the tissue could be a problem that 
reduces the imaging sensitivity. The coded excitation technique, which enhances the penetration 
and SNR without sacrificing much of the spatial resolution and raising the MI by transmitting 
longer coded signals through the tissues and compressing the receiving signals, could be sought as 
a potential solution [123]–[126].  
6.2.6 Conclusions 
In this study, we successfully adapted the SRU technology to a clinical curve linear array 
that provides larger field of view and imaging depth for human kidney imaging and performed the 
pilot test on both healthy human subjects and CKD patients. The fine vascular network was 
reconstructed by SRU at the spatial resolution of 0.14 mm, which is smaller than one third of 
wavelength at 3.125 MHz. The overall kidney size reduction and vascular rarefaction was 
identified qualitatively and quantitatively in CKD kidneys compared to the healthy kidney with 
limited number of subjects. The efforts in this study initiated the translation of SRU technology 
into clinics, for which not many studies have been previously reported.  
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7.0 SRU Imaging of Vasa Vasorum in Rabbit Atherosclerotic Plaques 
The work presented in this chapter was reprinted from Q. Chen et al., “Validation of Ultrasound 
Super-Resolution Imaging of Vasa Vasorum in Rabbit Atherosclerotic Plaques,” IEEE Trans. Ultrason. 
Ferroelectr. Freq. Control, vol. 67, no. 8, pp. 1725–1729, Aug. 2020, doi: 10.1109/TUFFC.2020.2974747, 
with the permission of IEEE Publishing. © 2020 IEEE. 
7.1 Introduction 
Acute coronary syndromes and strokes are mainly caused by the atherosclerotic plaque 
(AP) rupture [127]–[132]. It has been reported that the dense neovasculature of vasa vasorum 
(VV), infiltrating into the AP core and resulting in excessive micro-vasculatures, may lead to 
intraplaque hemorrhage, which plays a critical role in AP rupture [131], [133]–[135]. Thus, 
adventitial VV and their infiltration into the AP core is together a key evidence of AP progression 
and vulnerability [131], [135]–[140]. Therefore, a noninvasive imaging tool for detecting and 
monitoring the VV development near major vessels is of great importance for preclinical and 
clinical studies.  
However, due to its tiny size, it is challenging to identify VV in vivo. Contrast-enhanced 
magnetic resonance imaging [141]–[143], microcomputed tomography [144], [145], and optical 
coherence tomography [146], [147], have successfully imaged VV with high spatial resolution in 
preclinical studies; however they exhibited limitations such as hazardous contrast agents, radiation, 
or poor imaging depth, respectively. Ultrasound (US) imaging has also been explored as a potential 
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modality for imaging micro-vessels. High-frequency intravascular US provides a high spatial 
resolution [148]–[151], but it is invasive. As a transcutaneous imaging approach, low-frequency 
CEU [152]–[154] does not provide sufficient spatial resolution within the acoustic diffraction limit 
(ADL). Until now, there is no well-established imaging technology that can visualize VV in a 
noninvasive, safe and high-resolution manner. 
As introduced in the above chapters, the emerging in vivo SRU imaging technology [37], 
[38], [155], [39]–[46] can provide unprecedented spatial resolution of microvasculater and has 
been sucssessfully tested on different animal models. Therefore, SRU imaging can also be a 
promising transcutaneous imaging tool for VV detection. In the previous studies, our group has 
already performed a pilot test for imaging the VV in the rabbit AP using the developed 
deconvolution-based SRU technology with spatio-temporal-interframe-correlation (STIC) 
algorithm that significantly improves the temporal resolution and mitigates the cardiac motion 
artifacts [42]. Despite successful in vivo demonstration of the technical capability of SRU in 
identifying VV in rabbit AP, a further systematic validation study comparing with both 
histopathological and anatomical evidence, is still required for future verification of the 
repeatability and reproducibility in VV identification. An established experiment protocol for such 
validation is needed for the extensive studies and would also benefit the research in other disease 






In this work, we introduce a protocol of SRU imaging for VV detection along with the 
systematic validations. The deconvolution-based SRU imaging technology was first performed in 
vivo on two rabbits of a well-established AP model [153] for identifying the VV in both injured 
and uninjured femoral arteries. The identification of VV by SRU was then histopathologically and 
morphologically verified by hematoxylin and eosin (H&E) and CD31 stain, and ex-vivo micro-
computed tomography (µCT) scan, respectively. 
7.2 Material and Methods 
7.2.1 Rabbit Atherosclerotic Plaque Model 
As shown in Figure 31(a), two New Zealand white male rabbits were fed a high-fat-high-
cholesterol diet (HFHC) (cholesterol 1%, peanut oil 2.5%, and fat 10%) for six weeks [153]. One 
week after the diet started, the balloon injury was performed in the right superficial femoral arteries 
of the two rabbits under anesthesia (ketamine 150 mg IM, xylazine 8 mg IM and 2.5% inhaled 
isofluorane) by using a 2F Fogarty balloon catheter (Edwards Life Sciences, USA) to induce the 
plaque development. The balloon catheter was introduced to the bifurcation area of the femoral 
artery, inflated to 2 atm, and moved back and forth several times to induce the injury to the vessel 
wall with the guidance of high-frequency ultrasound scan (Vevo2100, FUJIFILM Visualsonics, 
ON, Canada).   
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Figure 31 (a) Study timeline. (b) Signal processing procedure of SRU imaging. 
7.2.2 SRU Imaging and Validation Protocol 
At week 8, in vivo ultrasound imaging was performed on both injured and uninjured rabbit 
femoral arteries, followed with histology and μCT on the excised artery samples. The SRU 
imaging sequence was operated by a programmable ultrasound system (Vantage 128, Verasonics, 
Kirkland, WI) equipped with a 15.6 MHz linear array ultrasound probe (L22-14v, Verasonics, 
Kirkland, WI). The rabbit was prepared with femoral fur shaved, ear vein catheter placed, and kept 
anesthetized during the imaging process. Regular B-mode ultrasound imaging was used to locate 
the bifurcation area of the femoral artery. Then the probe was fixed to a probe holder to ensure the 
stability during the following data acquisition process. A bolus of 0.2 mL MBs (Definity, diameter 
1- 4 µm, Lantheus Medical Imaging, MA) was intravenously administrated through the ear vein. 
About 30 seconds after injection, RF data of 3000 effective frames were acquired using multi-
angle (-3°, -1.5°, 0°, 1.5°, 3°) plane wave imaging using two cycles per pulse at an effective frame 
rate of 500Hz. The ultrasound scan was repeated on another imaging plane separated by image 
slice thickness of about 0.5 mm for both injured and contralateral uninjured side.  
Upon completing SRU scan, a relatively large block of femoral tissues (~4 cm) containing 
femoral arteries from both injured and uninjured sides of the first rabbit were excised after 
euthanasia and formalin fixed. Then, the bifurcation area in the tissue was located with the 
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guidance of 3D ultrasound scan (Vevo2100). The tissue around the bifurcation was further 
trimmed out into a small block of 0.5 mm for paraffin embedding and sectioning. The slices were 
processed with H&E stain for plaque identification and Immunohistochemistry of CD31 
(ab199012, Abcam, Cambridge, MA, USA) stain for identification of neovessels surrounding the 
plaque.  
Upon completion of SRU scan of the second rabbit, the animal was euthanized and 
perfused with 50 mL rubber-based radiopaque contrast agent (Microfil, Flow Tech, Carver, MA) 
through the access to femoral artery at a constant flow rate of 5 mL/min using a syringe pump (KD 
Scientific, Holliston, MA). Twenty minutes later when the contrast agent was fully cured, the 
femoral arteries were excised along with a block of the surrounding (~30 mm in diameter and 65 
mm in length) connective tissues and fixed in formalin solution. With the help of CT scan with a 
relatively large field of view (40×40mm) and a medium spatial resolution (25 μm) (Inveon, 
Siemens, Tarrytown, NY), the tissue block was trimmed to the appropriate size (~12 mm in 
diameter), enabling a higher resolution scan by Scanco µCT 50 (ScCANCO Medical, Switzerland) 
system with 10 µm voxel size, 55 kVp, 800 ms exposure time, in 70% alcohol as a medium. The 
study was approved by the Institutional Animal Care and Use Committee (IACUC) at the 
University of Pittsburgh. 
7.2.3 SRU Signal Processing Procedure 
The general signal processing procedure (Figure 31b) is similar to that describe in Chapter 
4. As shown in Figure 31(b), the acquired RF channel data were first reconstructed to IQ-data 
using the delay-and–sum beamforming. Then the echo signals only from MBs were extracted by 
applying the singular value decomposition (SVD) based spatio-temporal clutter filter [51] on the 
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IQ-data. The tissue component over IQ data in 500 ensembles were suppressed by the clutter filter. 
After envelope detection and thresholding, the images containing only MB signals were 
interpolated to achieve sub-wavelength precision and deconvolved using RL deconvolution 
algorithm with pre-estimated PSF to localize the center of each MB [64]–[66]. All 3000 frames 
over the 6 seconds of the localized MBs in blood flow were realigned by synchronizing to the 
estimated cardiac cycle according to the MB density using the STIC based data re-alignment 
algorithm [42]. The final SRU image in one effective cardiac cycle was reconstructed by summing 
up 300 frames of deconvolved signals rearranged from about 30 cardiac cycles. The entire SRU 
image reconstruction was processed off-line in MATLAB (Mathworks, Natick, MA). 
7.3 Results and Discussion 
The first two columns of Figure 32 depict the B-mode, and overlaid SRU and B-mode 
images of the area near bifurcation, where the balloon injury was performed, of the uninjured and 
injured femoral arteries of the first rabbit. The femoral artery and surrounding VV, as well as some 
other small vessels nearby, were clearly identified by SRU. For each side, two sets of images 
acquired from two different imaging planes separated by image slice thickness of ~0.5 mm are 
shown. Note the SRU images at systole were selected for consistent comparison and better 
demonstration of VV. The AP formation was observed in the injured femoral artery. The vessel 
wall boundaries manually identified based on echogenicity from B-mode images were marked 
with white dashed lines. In the SRU images of the second column, white arrows indicate the 
identified VV in the adventitia and within the plaque. Significant abundance of VV was found in 
the injured side compared to the uninjured side. The VV density inside the vessel wall was 
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estimated to be 3.75% for the injured side and 1.04% for the uninjured side. The plaque formation 
was confirmed by histology with H&E stain (A5, B5). In B5, plaque was identified inside the 
endothelium in the tunica intima of the lumen drawn with yellow solid line. The last two columns 
display the immunohistochemistry with CD31 stain identifying the vessel in the corresponding 
section. VV was enriched abnormally in the injured side and penetrating into the plaque 
characterized in H&E stain. The population of VV around adventitia and plaque measured in CD31 
stain in the injured side was approximately 3-fold higher than the uninjured side, which closely 
matched with the estimation by SRU.  
 
Figure 32 B-mode, SRU overlaid on B-mode images, H&E, and CD31 stain of the contralateral uninjured 
side (A) and injured side (B) of the femoral arteries from rabbit #1. Two image slices separated by ~ 0.5mm 
were taken by ultrasound on each side. Column 1 and 2 depict the B-mode and SRU images of area that were 
suspected for plaque and VV development. The white dotted lines represent vessel wall and white arrows 
indicate VV. Significant plaque development was evidenced in the injured side (B5) and verified by H&E 
stain (column 3). A significantly increased VV population in the adventitia area and VV infiltrated into the 
plaque were identified from SRU images (column 2) and validated by CD31 stain (column 4, 5). 
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In Figure 33, the SRU images on the injured side of the second rabbit were compared with 
the contralateral uninjured side along with the µCT images for anatomical validation. AP 
formation and increased VV population on the injured side were shown in SRU images. The VV 
density inside the vessel wall was estimated to be 6.30% on the injured side and 1.94% on the 
uninjured side. Column 3 shows a general view of the corresponding µCT images around the 
bifurcation. Column 4 provides magnified views at 0° and 270° of the ROI, denoted in yellow 
dashes rectangle in column 3. In the μCT images of the injured side (B), much crowded small 
vessels were identified in the area near the bifurcation, where the balloon injury was performed, 
marked by a white arrow (B5, B6, B7), while no such feature was found in the corresponding area 
(A5, A6, A7) on the uninjured side(A). Thus, the abnormally populated VV network was directly 
evidenced by μCT. Figure 34(a) shows the SRU image with a larger field of view in the imaging 
plane of B4. The typical VV structure inside the white dashed rectangle at about 6 mm away from 
bifurcation was also identified at the same location in the μCT image (B6 in Figure 33). Figure 
34(b) and (c) show the zoomed-in SRU and μCT image of the area. The estimated size of the vessel 
by μCT (~121 μm) supports the estimation by SRU (~134 μm). 
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Figure 33 B-mode, SRU overlaid on B-mode, and μCT images of the uninjured side (A) and injured side (B) 
of the femoral arteries from rabbit #2. Column 3 shows the 3D µCT images of the harvested arteries. Column 
4 displays ROI marked in yellow box in column 3, with higher magnification at 0° and 270° view. Increase of 
VV population was observed in injured side compared to uninjured side by SRU, and evidenced by 




Figure 34 (a) Full view of femoral artery in the imaging plane of B4 in Figure 33. White dashed rectangle 
marks the area where excessive VV development around the plaque is identified. (b) Zoomed-in SRU image 
of the area. (c) The matching μCT image of the same area. 
 
It should be noted that although overall VV proliferation and some specific VV in SRU 
images were evidenced by µCT, the complete comparison in 3-D with ex-vivo µCT was hindered 
due to the limited imaging slices of SRU. Therefore, 3-D ultrasound scan would be encouraged to 
provide volumetric information and more robust correlation with µCT. There are also limitations 
in our SRU imaging technology. Although the VV detected by our SRU approach compare 
reasonably well with histology in vessel density and mCT in morphology, it should be noted that 
there could have been very tiny VV with very slow blood flow undetected by applying a SVD 
filter with a fixed parameter that is optimal only for a nominal VV blood flow speed range. In the 
future, we would explore a method to adaptively extract the vessels at different blood flow speed, 
for example by temporally adjusting data arrangements or applying 3-D SVD filtering technique 
that can differentiate slow-speed from fast-speed flow [156]. The RL deconvolution algorithm we 
applied in image reconstruction was shown to be able to resolve crowded microbubbles 
individually and thus allowed for a greatly increased temporal resolution [42]. However, it should 
be noted that since the RL deconvolution algorithm is an iterative maximum likelihood method, 
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the performance can be affected in some area where microbubbles are too close to each other. 
Moreover, the RL deconvolution algorithm depends on the accuracy of the pre-defined PSF. A 
fixed PSF was applied in the deconvolution process, while the actual PSF varies in different 
imaging depth although the difference might remain small. To improve the accuracy of the 
microbubble center localization, a deconvolution algorithm using adaptive PSF needs to be 
investigated. 
 
Overall, the abnormal proliferation of adventitia VV around rabbit femoral arteries and 
their infiltration into AP along with plaque development can be detected by SRU imaging. The 
SRU scan was validated by histology stains as a gold standard for histopathology changes and by 
µCT as a directly visualized characterization with high resolution. While the overall VV density 
and distribution vary in different vascular beds in normal conditions, the roles of VVs in the 
formation and progression of atherosclerosis are considered to be similar in their proliferation and 
infiltration [157]. Thus, the validation in femoral artery can also promote the investigation in other 
vessel beds such as carotid and coronary arteries. Since the systematic validation procedures for 
SRU in identifying VV in AP were established in this study, further extended studies using a larger 
group of animals including a longitudinal monitoring can be designed. As a long-term goal, 
translation of the SRU technology for predict the AP rupture by imaging VV in human 
atherosclerotic disease can be envisioned. These established logistics and experiment protocols 




In the study, SRU imaging was successfully applied for identifying the VV in the rabbit 
AP. The robustness of the imaging performance was validated histopathologically by H&E and 
CD31 stain, and morphologically by µCT scan. The imaging and validation protocols of VV 
imaging using SRU were established. These protocols may pave the way for future extended 
experiments on a larger group of animals for investigating SRU as a noninvasive transcutaneous 
imaging tool for VV identification and characterization, as well as other biomedical applications. 
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8.0 Conclusions and Future Directions 
In this dissertation, we demonstrate the development of two novel ultrasound technologies 
based on the idea of tracking and locating small particles. 
In Chapter 2 and Chapter 3, we focus on the development of ultrasound tracking technology 
for the artificial acoustically actuated microswimmers. The proof-of-concept of the proposed 
ultrasound tracking approach, which has never been suggested before, was first validated in a 2-D 
setup in vitro by comparing with the synchronized camera tracking. Subsequently, for the practical 
application of the microswimmer that navigates in the biomedical environment in situ, a 3-D 
ultrasound tracking system using two clinical probes that were translated by the step motors to 
track the arbitrary 3-D motion of the lab-made 3-D microswimmer was designed. The system 
provides a relatively high tracking accuracy by comparing with the camera as demonstrated in the 
in vitro experiment. Overall, this work proposed a promising approach for tracking the motion of 
the microswimmers in biomedical applications and built a solid foundation for future efforts for 
the clinical translation of the microswimmer technology. As the next step, the ex vivo validation   
using an excised animal organ is sought before in vivo preclinical study. The eventual goal of the 
research program is the development of the microswimmer technology combining the propulsion, 
tracking and feedback control strategies together, which will allow tasks such as drug delivery in 





In Chapter 4 through Chapter 7, we aimed at the development of the SRU imaging 
technology. The developed deconvolution-based SRU imaging achieved a spatial resolution 
smaller than one third of wavelength, which is beyond the acoustic diffraction limit, as validated 
firstly in vitro using vessel mimicking microfluidic channels, and demonstrated subsequently in 
the animal and human subject studies. The validation using custom-designed microfluidic chip as 
the ground truth on the scale of under tens of microns was performed for the first time to the best 
of our knowledge for SRU imaging. This proposed test method could be a practical scheme for the 
future studies in which the imaging capability of SRU imaging can be systematically tested. 
Through the in vivo preclinical animal studies, fine microvascular network in high spatial 
resolution was reconstructed, which allowed for the quantitative assessment of vascular changes 
due to the disease progression. In the application on the mouse AKI model, the capability for 
noninvasive and quantitative assessment of the changes in kidney morphology and vasculature, 
including size, rBV, vessel density and tortuosity, was demonstrated. The vessel density 
measurement by SRU correlated well with the histological measurement, which evidenced the 
potential of SRU as a noninvasive diagnostic tool for the progressive kidney disease. Subsequently, 
the SRU algorithm was configured to the clinical curved array probe and successfully applied on 
human subjects by identifying the size and vascular changes between healthy and CKD kidneys. 
These results show a great potential of SRU imaging as a diagnostic tool for kidney diseases. In 
the VV study, the capability of SRU imaging for identifying the VV in the rabbit AP was shown, 
which was validated with histology and μCT. The established imaging and validation protocol 
would facilitate future similar studies for imaging the VV. As the future direction of the SRU 
project, the further extended experiments on larger groups of subjects or animals are required to 
promote the clinical translation of this technology. In parallel with the translational efforts, SRU 
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algorithm using deep learning approach, which has the potential to achieve a higher spatial and 
temporal resolution under the conditions that the microbubbles are not uniformly distributed, will 
be investigated. A systematic validation of further advanced SRU algorithms and different 
operating frequencies using a well-designed microfluidic chip with various sizes of the channels 
that separated in various distances is planned.  
We envision that a unique tool for various biomedical applications of the novel 
microdrones for diagnosis and drug delivery can be developed by integrating novel SRU 
technology with a reliable tracking capability of microparticles. For the long-term goal of the 
research program, we seek to combine the microswimmer tracking and SRU imaging technology 
to perform in situ tasks inside the human body, such as providing enhanced contrast of the very 
tiny vessels aided by the microswimmers propelling through or providing the detailed structure by 
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